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Abstract

The objective of this study is to address some important questions associated with stomach
cancer patients using the data from the Surveillance Epidemiology and End Results (SEER)
program of the United States. To better understand the behavior of stomach cancer, we first
perform parametric analysis for each patient group (white male, white female, African American
male, African American female, other male and female) to identify the probability distribution
function which can best characterize the behavior of the malignant stomach tumor sizes. We
evaluate the effects of patients’ age, gender and race on the malignant stomach tumor sizes by
using quantile regression models, which gives us a better understanding of the behavior of the
malignant stomach tumors.

We also developed statistical models with respect to patients’ malignant stomach tumor size as a
function of age for different races and gender group, respectively. The developed models were
evaluated to attest their prediction quality. Furthermore, we have identified the rate of change of
the malignant tumor size as a function of age, for gender and race.

We evaluated the routine treatment of stomach cancer using parametric and nonparametric
survival analysis. We have found that stomach cancer patients who receive surgery with
radiation together have a better survival probability than the patients who receive only radiation.

ix

We performed decision tree analysis to assist the physician in recommending to his patients the
most effective treatment that is a function of their characteristics.

x

Chapter 1
Introduction
1.1 Cancer

In medical research, the tumor refers to the cells’ changing abnormality that is not
necessarily meaning the body tumor. Some body parts of the cells will result in
uncontrolled proliferation by the disease (www.wikipedia.org). In 2017 in USA, there
will be an estimated 1,688,780 new cancer cases and 600,920 cancer deaths. That is
approximately 4,630 new cases and 1,650 deaths per day. From 1991 to 2014, the total
cancer death rate was reduced 25% than the expected (www.cancer.org). Such progress
benefitted from treatment improvements and earlier diagnoses.

1.2 Stomach Cancer

According to the American Cancer Society, stomach cancer is the fifth leading cause of
cancer and third leading cause of death from stomach cancer. Stomach cancer, also called
gastric cancer, is a cancer that starts in stomach. Some people like to use “stomach” to
mention the body parts between the pelvic and the chest. The medical term for this area is
called “Abdomen”. Stomach cancer should not be puzzled with other cancers that can
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exist in the abdomen, like colon cancer, liver cancer because those different cancers have
different treatments, different symptoms, and different outlooks.

In 2017, there are about 28,000 cases of stomach cancer will be diagnosed (17,750 men
and 10250 women) and about 10,960 people will die from this type of cancer (6,720 men
and 4240 women) that was estimated by American Cancer Society. If the physicians find
the stomach tumor while only in the stomach, the 5-year survival rate is about 65%. If
they find the stomach tumor spread to areas near your stomach or lymph nodes, the 5year survival rate is about 30%. If they find the stomach cancer spread far away from the
stomach, the 5-year survival rate will be reduced to about 5%. Thus, the overall 5-year
survival rate of all people with stomach cancer in the United States is about 29%. The 5year relative survival probability compares the observed survival of patient with stomach
cancer to what is expected for the person without stomach cancer. Since some people
may die from other disease or other types of cancer, this is a better way to see the impact
of cancer on survival. This survival rate has improved over the past 30 years. The most
important reason that the total survival probability is pretty low in the United States is
that most of stomach cancer patients are diagnosed at a later stage. The stage of the
cancer plays a major role of the survival rate. The stage of a cancer is a description of
how far the cancer has extend. The stomach cancer’s stage is very important for the
physicians to choose the best treatment for their patients. There are two types of stages
for stomach cancer patients. The clinical stage of the stomach cancer is the best time for
the doctors to treat the cancer of their patients based on the results of physical exams,
endoscopy, biopsies, and any imaging tests such as CT scans, etc. Once the surgery is
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done, the pathologic stage can be determined using the same results from the clinical
stage.

A risk factor will affect patients’ chance of getting a cancer. Different cancers always
have different risk factors. There are several risk factors for stomach cancer. As shown in
Figure 1.1, Gender, age, Ethnicity, Geography, Helicobacter pylori infection, Tobacco
use, diet seem to play a role in raising the risk of a stomach cancer.

Smoking
Exposure to
asbestos

Working in
coal, metal,
timber, or
rubber
industries

Overweight

stomach
cancer

A diet high in
smoked,
pickled, or
salty foods

stomach
surgery for an
ulcer

Certain genes

Epstein-Barr
virus
infection

Type A blood

Figure 1.1: potential risk factors of stomach cancer

Stomach cancer is a very common cancer among East Asian people, especially in Japan.
Averagely, the stomach cancer incidence is about 60 per 100,000 people. In 2007, Japan
Cancer Society reports that one third of deaths were related to stomach cancer. Almost 70
to 90 percent of all stomach cancers begin with Helicobacter pylori, or H. pylori
infection. The H. pylori bacteria spread by unwashed or undercooked foods. The
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Japanese diet is characteristically high in seasoned foods. Salted food consumption is one
of the most important causes of increased stomach cancer risk. In Japan, there about 30
out of 100,000 people will develop stomach cancer in their whole life. The Japanese
government encourages their people to take screen test for stomach every year once they
older than age 40. That is the best way to find stomach cancer and detect it during the
earliest stage.

There is no sure way to prevent stomach cancer, but as the stomach tumors grow, the
patients may have more serious symptoms as shown in Figure 1.2 below. The best
treatment options for stomach cancer patients are Surgery, Chemotherapy, Targeted
Therapy, and Radiation Therapy. The doctors often suggest their patients to use two or
more of those treatment methods. But they do not know which treatment is the best for
their patients. Thus, we will also want to weight the benefits from each different
treatment and their potential side effects. The treatment selection depends on many
factors. The location of the tumor and the stage are very important for the doctors and
patients to consider. The physicians would also take the patients’ age, gender, body
situation, and other factors into account.

4

stomach
pain
Trouble
Swallowing

Blood in
your stool

Yellowish
eyes or skin

Vomiting

stomach
tumors
grow
Swelling in
your
stomach

Weight loss
for no
reason

Constipation
or diarrhea

Weakness or
feeling tired
Heartburn

Figure 1.2: more serious symptoms as stomach tumors grow

Researchers have reported parametric models that are similar to the Cox regression
(Moghimi-Dehkordi, Bijan, et al. 2008) method. Patients aged 60-75 and >75 years at
diagnosis had an increased risk for death. Although the hazard ratio in the Cox model and
other parametric models are approximately similar from the AIC criteria. The
Exponential and Weibull probability distributions are the most favorable distributions for
determine survival analysis. The survival probability and the risk of stomach cancer death
among the patients with screen-detected cancer and patients with interval cancer were not
significantly different in the annual endoscopic screening (Hamashima, Chisato, et al.
2015). These results suggest that the potential of endoscopic screening in reducing
mortality from gastric cancer. Missing value imputation is increasing the estimate of
precision and accuracy (Moghimbeigi, Abbas, et al. 2014). The survival rate in Japan
was clearly higher than those in the other countries (Matsuda, Tomohiro, and Kumiko
5

Saika, 2013). The high survival rate for Japanese patients could be related to the stomach
cancer screening and abundant experience in treatment according to the high incidence
rate. Patients who survive from gastric and gastroesophageal junction more than 3 years
after diagnosis have demographic and pathologic characteristics distinct from those who
do not survive (Kunz, Pamela L., et al. 2012). The survival of stomach cancer patient
diagnosis appears to be increasing (Hansson, Lars-Erik, Pär Sparén, and Olof Nyrén,
1999). The reasons for this are probably multifactorial and are likely to include
improvements in anesthesiologic and surgical management. Research scientists have
shown that patients’ age, gender, and tumor location are significantly independent
prognostic factors for overall survival in patients with metastatic gastric cancer (Yang,
Dongyun, et al. 2011).

1.3 Research Data
In 1973, the National Cancer Institute funded the Surveillance, Epidemiology, and End
Results program (SEER). The SEER program provides national leadership in the health
science of cancer surveillance as well as analytical tools and methodological expertise in
interpreting, analyzing, collecting, and disseminating reliable population-based statistics.
The SEER database is a premier source for various types of cancers in the United States.
The SEER program collects population-based cancer registries from 20 different
locations across the United States which are Alaska Native Tumor Registry, Arizona
Indians, Cherokee Nation, Connecticut, Detroit, Atlanta, Greater Georgia, Rural Georgia,
San Francisco-Oakland, San Jose-Monterey, Greater California, Hawaii, Iowa, Kentucky,
Los Angeles, Louisiana, New Jersey, New Mexico, Seattle-Puget Sound and Utah. The
6

information about cancer registries covers 28% of the population in the United States by
collecting complete and accurate data on all kinds of cancers that have been diagnosed.
The SEER cancer statistics review, which is a report of the most recent cancer incidence,
mortality, survival, prevalence, and lifetime risk statistics, are published by the
Surveillance research program of National Cancer Institute. In the present study, there is
a total of 11,462 records of stomach cancer patients from the year 2004 to 2013 were
obtained from the SEER program. There are 7,149 males (7,115 malignant) and 4,313
females (4,279 malignant) stomach patients. The probability of tumor in stomach not to
be malignant is 0.0048 for male and 0.0078 for female. Our research will focus on the
malignant stomach patients.

1.4 Parametric Analysis
The basic idea of parametric analysis of a given set of data is to identify, if possible, the
probability distribution function that characterizes the phenomenon that is represented by
the given data. Based on the specific probability distribution, we can obtain the important
approximate estimates from the parameters such as expected mean, standard deviation,
and confidence limits, etc. In Chapter 2, our objective is to find if there is a well-known
probability distribution that can be used effectively to characterize the behavior of the
stomach cancer patients’ tumor size. We first test if there is a significant difference of the
average malignant tumor size between the patients’ gender and race. We found that the
average malignant tumor size is different by patients’ gender and race, respectively. In
addition, we utilized three goodness of fit tests, Kolmogorove-Smirnov, AndersonDarling, Chi-Square, to identify the best probability distribution function which can
7

characterize the stomach patients’ malignant tumor size. We found that expected average
stomach tumor size of males is higher than that of females and African American patients
have the largest expected average stomach tumor sizes. The useful information such as
expected malignant tumor size along with its variance and confidence limits will assist
physicians to make appropriate decisions with a given degree of assurance. Furthermore,
there is an exponential growing behavior between the size of a tumor and the probability
of the tumor being malignant. When the tumor size is 10 millimeters or above, it has a
99.6% or higher chance that the tumor is malignant. Such findings and the graphical
figures of the probability density functions and the cumulative distribution curves could
provide assistance for physicians to understand the probabilistic behavior of the stomach
tumor size.

1.5 Quantile Regression Model
The average malignant stomach tumor size is often insufficient to explain the
probabilistic behavior of malignant stomach tumor size. Standard least square estimates
only provide a summary of the risk factors on the average malignant stomach tumor
sizes, which may hide important elements of the underlying relationships. In Chapter 2,
we found the best probability distributions are highly skewed Wakeby probability
distribution, three parameters Weibull probability distribution and Dagum probability
distribution, which means the standard least squares assumption of normally distributed
errors fails to hold. The quantile regression can exhibit a comprehensive picture when
both upper and lower quantiles of the distributions of response are our interests. In
Chapter 3, we developed a statistical quantile regression model to describe the effects of
8

patients’ race, gender, and age on the sizes of malignant stomach tumors. Based on the
results of our statistical quantile regression model, we have identified there is a
significant difference between male and female patients. For instance, for the 60th
quantile, the malignant tumor size of male patients is 7.89 millimeters larger than females
when the other covariates hold the same level. Such information is important to medical
doctors to address the procedural and clinical strategies for their patients. Moreover, our
statistical quantile model reveals a significant difference of stomach tumor size between
patients’ race. For instance, for the 45th quantile, African American patients’ malignant
tumor size is 9.49 millimeter bigger than other race patients’. In addition, we found the
patients’ age also is a significantly contribution factor for estimating the malignant tumor
size. For the 25th quantile, the malignant tumor size increases 0.125 millimeters for oneyear increase in patients’ age. Our developed statistical quantile regression model gives a
more comprehensive comparison of malignant tumor size. Such findings are extremely
important for medical doctors to improve their treatments for their patients.

1.6 Statistical Modeling
Statistical modeling is a simplified, mathematically formalized way to approximate
reality and optionally to make predictions from this approximation. Under a set of
assumptions, we develop the statistical model based on the sample data. A good
statistical model can be used to identify the attributable variables to the response variable
and to identify the significant interactions among those explanatory variables which
contributes to the response significantly. Once we have a good statistical model, we can
use it for prediction and forecasting. In addition, we can do surface response analysis. An
9

easy way to estimate a first-degree polynomial model is to use a factorial experiment or
a fractional factorial design. This is sufficient to determine which explanatory variables
affect the response variable(s) of interest. Once it is suspected that only significant
explanatory variables are left, then a more complicated design, such as a central
composite design, can be implemented to estimate a second-degree polynomial model,
which is still only an approximation at best. However, the second-degree model can be
used to optimize (maximize, minimize, etc). Furthermore, a good statistical model can be
used to identify how the responses vary for different categories. Moreover, a good
statistical model can be used to investigate the relationships between explanatory
variables and the response variable. The main objective of Chapter 4 is to identify the
stomach cancer tumor size as a function of patient’s age. The statistical analysis research
was performed under different race and gender groups, respectively. We developed a
nonlinear statistical model to fit the observed data and the residual analysis was
performed to help us identify the appropriate fit. The differential equation guides us to
figure out how the rate of changing mean size of malignant tumor when the patients
increase the age.

1.7 Decision Tree Analysis

Decision making always plays a very important role in many fields of research, especially
in cancer research. The important idea of survival tree analysis is to split the given
sample into subgroups by continuous spiting of the initial node into child nodes based on
the uniformity of within-node instances or separation of between-node instances with
respect to our risk factors. For each node, risk factors are tested based on the splitting
10

criterion. After the node is divided into two child nodes according to the value of the
attribute variable, we repeated the process for each child node. The whole process of a
decision tree is shown below in Figure 1.3.

Root Node
(Display Total Data
)
Input Field Used as Splitting Criterion

Field Value 1
.
.
.
.
Field Value n

Field Value n+1
.
.
.
.
Field Value N

Branch or

Node or Leaf

Segment
Bottom nodes are leaves

Figure 1.3: Illustration of the Decision Tree
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In Chapter 5, the objective is to identify the stomach patients who could potentially
benefit from surgery and those who could be very risk to take the surgery treatment,
because the radiation or surgery may cause some side effect for the patients. We first
perform the nonparametric and parametric survival analysis for comparing the two
treatments’ effect for male and female stomach cancer patients, respectively. Our result
identified that the stomach patients who receive the combination of radiation and surgery
have the most significant effect than the patients who receive only the radiation treatment
with respect to the survival time. However, the decision tree model gives us the more
powerful result. Based on the decision tree analysis, we found the more detailed
treatment difference between different subgroups of the stomach cancer patients. For
instance, a male stomach patient aged 70 to 76 years old with malignant tumor size
between 40 and 58 millimeters, the combination of radiation and surgery shows the better
effects on the survival time. Such important information could assist stomach cancer
physicians to choose the suitable treatment for stomach cancer patients.

12

Chapter 2
Parametric Analysis of Malignant Stomach Tumor Size
2.1 Introduction
In medical research, the tumor refers to the cells’ changing abnormality that is not
necessarily meaning the body tumor. Some body parts of the cells will result in
uncontrolled proliferation by the disease. Benign and malignant tumors are two types of
tumors.

Benign tumors grow slowly and have smooth surface. They do not inbreak the normal
tissue cells. A membrane usually envelops around the tumor body, so that it distinguishes
between normal and abnormal cells. Normally, benign tumors will not lead to death and
most of them can be completely removed.

Malignant tumors are cancerous and made up of cells that grow out of control. They
break nearby tissues and spread to other parts of the body and distinguishes themselves
from benign tumors. Sometimes cells move away from the primary cancer site to other
organs and bones where they continue to grow and form another tumor at that site.

There is extensive research about the tumors of the stomach, especially cancer tumors.
The research only provides descriptive information but doesn’t clearly explain the
13

changes in the disease rates, among others. This studies objective is exploring the causes
for stomach cancer, among others. It is important to understand the natural history of the
stomach cancer. In respect to this objective, we chose the malignant tumor sizes as the
response variable and identified a statistical behavior of the tumor size. In the present
study, we performed parametric analysis on the malignant tumor size of stomach cancer
datasets obtained from the Surveillance, Epidemiology and End Results (SEER) database
from 2004 up to 2013. We proceeded to identify the probability distribution functions
that characterize the probabilistic behavior of malignant tumor size as a function of
gender.

2.2 Data Description
A total of 11,462 records of stomach cancer patients from the year of 2004 to 2013 were
obtained from SEER program. The SEER database is a premier source for various types
of cancers in the United States. The information about cancer registries covers 28% of the
population in the USA by collecting the data on all cancers that have been diagnosed. The
SEER cancer statistics, which is a report of the most recent cancer incidence, mortality,
survival, prevalence, and lifetime risk statistics, is published by the Surveillance research
program of National Cancer Institute. The scope and purpose of this work are consistent
with a report to the Senate Appropriations Committee (Breslow, 1988), which
recommends that a broad profile of cancer can be presented to the American public on a
routine basis.
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Figure 2.1, given below, gives a characteristic network and presentation of the data that
we will be working in the present study. This data is broken down to malignant and
benign stomach cancer patients and as a function of gender and race.

Stomach
cancer
11,462

Male
7,149

Whites
4,945

Female
4,313

Malignant
7,115

Benign
34

African
American
864

Other
1,306

Whites
2,662

Malignant
4,279

Benign
34

African
American
658

Other
959

Figure 2.1: Schematic diagram of stomach cancer patients with malignant and benign tumor sizes for
males and females.

In this study, we analyzed data on malignant primary stomach tumors diagnosed from
2004 to 2013 for the following registries: San Francisco-Oakland, Connecticut,
Metropolitan Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Metropolitan
Atlanta. The dataset includes 11,394 primary malignant stomach tumor records and 68
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benign stomach tumor records. This analysis focuses only on the malignant tumors
measured in millimeters.

Using the information from the given data, we address the following questions:
1. What is the probability distribution function that characterizes the behavior of the
malignant tumor sizes for each patient group?
2. Is there a significant difference in the mean cancerous tumor sizes between male
and female patients?
3. If the answer to the second question is “yes”, is there still a significant difference
of the mean tumor sizes for male and female among different race groups (White,
African American, Other)?
The answers to the above questions are important on how we proceed with inferential
statistical analysis and modeling of the data.

2.3 Statistical Analysis of Gender and Race
Although Figure 2.2 below shows that the frequencies histogram plots of male and
female are very similar, we still performed the parametric two-sample t-test and the
nonparametric Kruskal-Wallis test to test for significant difference between the two
genders. Based on the extremely small values, we rejected the null hypothesis at a level
of significance of 0.0001 and concluded that there is a significant different between the
mean malignant tumor sizes of male and female stomach cancer patients.
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Figure 2.2: Frequencies Histogram plots of malignant tumor size for Female (left) and Male (right)
patients.

Furthermore, we tested the mean of the malignant tumor size for males and females in
different race groups (White, African American, Other), respectively. The extremely
small values indicate that there is a significant difference among race groups at a
significance level of 0.0001. In the next section, we introduce the best-fitted probability
distribution functions for each different race group and by gender, respectively.

2.4 Probabilistic Behavior of Malignant Stomach Tumor Sizes
Parametric analysis is performed to determine the best fitted probability distribution
function that characterizes the malignant tumor size behavior by gender and race.
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The most important point of the parametric method is that we can use a small set of
parameters to represent a large amount of information for the data. We can also get useful
information from the estimated parameters. Therefore, we can use probabilistic models of
malignant tumor sizes to explain the biological interpretation, among others.
Furthermore, the useful information can be directly drawn from the estimated parameters
for different subgroups, provided that the differences in the estimated parameters have a
clear biological interpretation. Thus, one of the certain properties required for the
probabilistic models of distributions of malignant tumor sizes is their biological
interpretation. To better performing the analysis, we have partitioned the data set with
regard to races of White, African American and the other races as well as the patient
gender.

After about 50 different classical parametric probability distributions were used to fit the
data, we obtained the best-fitted probability distributions. We applied three commonly
used goodness-of-fit tests, i.e., Kolmogorov-Smirnov (Stephens, 1974) test, AndersonDarling (T.W. Anderson, 1952) test and Chi-Square (H. Chenoff, 1954) test to determine
the best probability distribution functions that characterize the malignant tumor sizes for
male and female patients in different race groups. Finally, we identified that the bestfitted probability distribution functions that characterize the malignant tumor sizes are the
Wakeby (Houghton, 1978) probability distribution for white female, African American
female and other female race, the three-parameter Weibull (Cohen, 1965) probability
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distribution for white male and African American male, and the Dagum (Kleiber, 2008)
probability distribution for other male race patients, respectively.

2.5 Parametric Analysis of Malignant Tumor Sizes for Female
2.5.1 Parametric Analysis of Malignant Tumor Sizes for White Female
We have found that the Wakeby probability distribution is the best-fitted probability
distribution function that characterizes the malignant tumor size for white female patients
with stomach cancer. The Wakeby probability distribution function is given by

𝑓(𝑥) =

(1−𝐹(𝑥))

𝛿+1

𝛼𝑡+𝛾

(2.1)

+ 𝜉, 0 < 𝑥 < ∞

where 𝛽, 𝛾 and 𝛿 are continuous shape parameters, 𝜉 and 𝛼 are location parameters, F is
the cumulative probability distribution function given by 𝑡 = (1 − 𝐹(𝑥))

𝛽+𝛿

.

. The following conditions are imposed:
1. 𝛼 ≠ 0 or 𝛾 ≠ 0,
2. 𝛽 + 𝛿 > 0 or 𝛽 = 𝛾 = 𝛿 = 0,
3. If 𝛼 = 0, then 𝛽 = 0,
4. If 𝛾 = 0, then 𝛿 = 0,
5. 𝛾 ≥ 0 and 𝛼 + 𝛾 ≥ 0.
By using the maximum likelihood estimation, we found that the approximate maximum
likelihood estimators of the parameters are,
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𝛼̂=58.697, 𝛽̂ =3.826, 𝛾̂=39.374, 𝛿̂ =-0.28324 and 𝜉̂=-0.36842.

The identified Wakeby probability density function and quantile probability distribution
function for white female patients are as follows:

𝑓(𝑥) =

(1−𝐹(𝑥))

−0.28324+1

58.697𝑡+39.374

− 0.36842,

(2.2)

where F is the cumulative probability distribution function and 𝑡 = (1 −
𝐹(𝑥))

3.826−0.28324

. The quantile function 𝑥(𝐹) is given by

𝑥(𝐹) = −0.36842 +

58.697
(1 − (1 − 𝐹)3.826 )
3.826

39.374

− −0.28324 (1 − (1 − 𝐹)0.28314 ).

(2.3)

We utilized the maximum likelihood estimates from Wakeby probability distribution to
plot the estimated probability density curve of malignant tumor sizes for white female
patients. Figure 2.3 illustrates that the identified distribution curve has a long right tail
and most of the malignant tumor sizes are within the range of 0 to 120 millimeters. We
plotted the estimated cumulative probability distribution function for white female
patients as shown in Figure 2.4. The cumulative probability distribution function is
explaining the characterize behavior of malignant tumor size. It assists us to find out the
probability of the quantiles of the random variables, among others. For example, we can
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easily find that about 80% of white female patients have malignant tumor sizes less than
or equal to 65 millimeters, etc.

Figure 2.3: Fitted Wakeby Probability Distribution Function of Malignant Tumor Size for White Female

From Figure 2.3, we can see that the approximate probability of a white female patient
has 32 millimeters malignant tumor size is 0.0142. And the approximate probability of a
white female patient has the malignant tumor size between 40 millimeters and 60
millimeters is 0.235 that is 𝑝(40 < 𝑥 < 60) = 0.235. And the probability of a white
female patient has the malignant tumor size is greater than 40 millimeters is about 0.495.
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Figure 2.4: Fitted Cumulative Wakeby Distribution Function (CDF) of Malignant Tumor Size for White
Female

The important statistical information using the Wakeby probability distribution are, the
expected malignant tumor size,

𝛼̂

𝛾̂

𝐸(𝑥) = 1+𝛽 ̂ + 1−𝛿 ̂ + 𝜇 ̂, 𝑤ℎ𝑒𝑛 𝛿 < 1.

(2.4)

and the variance of the malignant tumor size,

𝑉(𝑥) =

𝛼̂ 2
2

(1 + 𝛽̂ ) (1 + 2𝛽̂ )

−

2𝛼̂𝛾̂
(1 + 𝛽̂ )(1 + 𝛽̂ − 𝛿̂ )(−1 + 𝛿̂ )

𝛾 2̂

− (−1+𝛿 ̂)2 (−1+2𝛿 ̂) , 𝑤ℎ𝑒𝑛 𝛿 ̂ < 0.5.
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(2.5)

and the 95% confidence interval of the true malignant tumor sizes is given by

𝑃(𝑎 < 𝑡𝑟𝑢𝑒 𝑡𝑢𝑚𝑜𝑟 𝑠𝑖𝑧𝑒 < 𝑏) ≥ 0.95.

(2.6)

We have obtained the expected mean of the malignant tumor size to be 42.48 millimeters
for white female patients with a standard deviation of 27.64 millimeters. Moreover, we
are at least 95% confident that to the true malignant tumor sizes for white female
patients’ to be between 2.041 millimeters and 105.09 millimeters with at least 95%
confidence.

2.5.2 Parametric Analysis of Malignant Tumor Sizes for African American Female

After a very extensive search, we have identified that the Wakeby probability distribution
is the best-fitted probability distribution function that characterizes the malignant tumor
size for African American female patients with stomach cancer. The theoretical Wakeby
probability distribution was introduced in section 2.4.1. The approximate maximum
likelihood estimates of the five parameters are

𝛼̂=128.48, 𝛽̂ =8.3385, 𝛾̂=46.569, 𝛿̂ =-0.34268 and 𝜉̂=-0.91885.

Thus, the Wakeby probability density function that characterize the probabilistic behavior
of the malignant tumor size of African American female patients is given by
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𝑓(𝑥) =

(1−𝐹(𝑥))

−0.34268+1

128.48𝑡+46.569

(2.7)

− 0.91885, < x

where F is the cumulative distribution function and 𝑡 = (1 − 𝐹(𝑥))

8.3385−0.34268

.A

graph of the estimated Wakeby probability distribution function for African American
female patients with malignant stomach tumor size is given below by Figure 2.5.

Figure 2.5: Fitted Wakeby Probability Distribution Function of Malignant Tumor Size for African
American Female

The expected mean of the malignant tumor size was calculated to be 47.51 millimeters
and the standard deviation to be 28.66 millimeters for African American female patients
based on functions (2.4) and (2.5). This graph illustrates that the approximate probability
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of an African American female patient has 31 millimeters malignant tumor size is 0.0146.
And the approximate probability of an African American female patient has the
malignant tumor size between 40 millimeters and 60 millimeters is 0.243 that is 𝑝(40 <
𝑥 < 60) = 0.243. And the probability of an African American female patient has the
malignant tumor size is greater than 40 millimeters is about 0.558.

Figure 2.6 shows that about 80% of African American female patients have malignant
tumor sizes less than or equal to 73 millimeters. Furthermore, we are at least 95%
confidence to conclude that African American female patients’ malignant tumor size fall
in the interval (4.51 millimeters, 110.01 millimeters) by using the function (2.6).

Furthermore, the Wakeby cumulative probability distribution function is given by

𝑥(𝐹) = −0.91885 +

128.48
(1 − (1 − 𝐹)8.3385 )
8.3385

46.569

− −0.34268 (1 − (1 − 𝐹)0.34268 ).

Thus, a graphical form of F(x) is given below by Figure 2.6.
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(2.8)

Figure 2.6: Fitted Cumulative Wakeby Distribution Function (CDF) of Malignant Tumor Size for African
American Female

2.5.3 Parametric Analysis of Malignant Tumor Sizes for Other Female
Using the three popular goodness-of-fit tests that is, the Chi-square test, the Kolmogorov
Smirnov test and the Anderson Darling test, we have identified that the Wakeby
probability distribution also fits the malignant tumor size data for all other female race
patients. The approximate estimates of the five parameters that are given by

𝛼̂=108.16, 𝛽̂ =9.5265, 𝛾̂=48.728, 𝛿̂ =-0.38916 and 𝜉̂=-0.27848.

Thus, the identified Wakeby probability density function and quantile probability
distribution function for other female race patients are as follows:
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𝑓(𝑥) =

(1−𝐹(𝑥))

−0.38916+1

108.16𝑡+48.728

(2.9)

− 0.27848

where F(x) is a cumulative probability distribution function and 𝑡 = (1 −
𝐹(𝑥))

9.5265−0.38916

. The quantile probability distribution function is given by

𝑥(𝐹) = −0.27848 +

108.16
(1 − (1 − 𝐹)9.5265 )
9.5265

48.728

− −0.38916 (1 − (1 − 𝐹)0.38916 )

(2.10)

The graphical form of (2.9) and (2.10) are given by Figures 2.7 and 2.8, respectively.

Figure 2.7 below illustrates that the approximate probability of an other race female
patient has 27 millimeters malignant tumor size is 0.0152. And the approximate
probability of an other race female patient has the malignant tumor size between 40
millimeters and 60 millimeters is 0.231 that is 𝑝(40 < 𝑥 < 60) = 0.231. And the
probability of an other race female patient has the malignant tumor size is greater than 40
millimeters is about 0.516.
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Figure 2.7: Fitted Wakeby Probability Distribution Function of Malignant Tumor Size for Other Female

Figure 2.8: Fitted Cumulative Wakeby Distribution Function (CDF) of Malignant Tumor Size for Other
Female

From Figure 2.8 above, we can estimate that about 80% of other female race patients
have a malignant stomach tumor sizes less than or equal to 70 millimeters.
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We also calculated the estimated expected mean of the malignant tumor size to be 45.56
millimeters and the standard deviation to be 27.96 millimeters for other female race
patients. Furthermore, we are at least 95% confident that the true mean of the other
female race patients’ stomach malignant tumor size fall in the interval (5.27 millimeters,
110.85 millimeters) by using E.q (2.6).

2.5.4 Comparison of the Malignant Tumor Sizes for Female Patients
In this section, we are comparing the malignant tumor size for female patients by
different race group. Table 2.1 below displays the best-fitted distributions that
characterize the malignant tumor size for different race groups and the estimated
malignant mean tumor size for female patients in each race group. We found the Wakeby
probability distribution is the best fitted distribution that can characterize the behavior of
the malignant tumor size for female patients in different race group. When we test the
average malignant tumor size under different races (white, African American and other),
we reject the null hypothesis that they are equal. The African American female patients
have the largest expected malignant tumor size, which is 47.51mm. The white female
stomach cancer patients have the smallest expected malignant tumor size, which is
42.48mm. Confidence intervals both provide the probabilistic behavior of the malignant
tumors for each race group. This information will assist physicians to make appropriate
decisions with a given degrees of assurance. Also, additional information such as
confidence limits on the true size of the malignant tumor size will be useful to the
physicians. For example, for a white female patient we are at least 95% confident her
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malignant tumor size is within the range from 2.04mm to 105.09mm and her expected
malignant tumor size is 42.48mm.

Table 2.1: statistics of the malignant tumor sizes and confidence intervals for female patients

PDF

White

Wakeby

Expected

Standard

Mean

Deviation

95% Confidence Intervals

42.48

27.64

(2.041,105.09)

47.51

28.66

(4.51, 110.01)

45.56

27.96

(5.27, 110.85)

pdf

African

Wakeby

American pdf
Other

Wakeby

Race

pdf

We plotted the estimated probability distribution curves of malignant tumor size of
female patients for different race groups as shown in Figure 2.9 below. When the
malignant tumor size is less than 20 millimeters, the white female patients have higher
probability than the African American female and other female race patients do. When
the malignant tumor size is between 20 millimeters and 40 millimeters, the other female
race patients have higher probability. When the malignant tumor size is greater than 40
millimeters, the three race groups of patients have almost the same probability
distributions. And the approximate expected true malignant tumor size for white female,
African American and other female race patients are 42.48mm, 47.51mm and 45.56mm,
respectively.
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Figure 2.9: Fitted Distribution Curves of Malignant Tumor Size for Female Patients

Figure 2.10 below depicts the cumulative probability distribution curves of malignant
tumor size for different female race groups. The orange (white female) curve is slightly
higher than the other two lines. The green (other female race) line locates in the middle,
which means that for a fixed value of malignant tumor size, the cumulative probability of
white female patients is always greater than that of the other two race patients, and the
cumulative probability of other female race patients is between that of white female and
other female race. Moreover, the expected means of the malignant tumor size of female
patients are 42.48 millimeters for white female, 47.51 millimeters for African American
female and 45.56 millimeters for the other female race patients. The 95% confidence
intervals are (2.041, 105.09) for white female, (4.51, 110.01) for African American
female and (5.27, 110.85) for the other female race patients. These information is useful
for doctor to convey to their patients.
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Figure 2.10: Fitted Cumulative Distribution Curves of Malignant Tumor Size for Female Patients

The above graph shows that the probability of the malignant tumor size is greater than
84mm are 0.089, 0.124 and 0.109 for white female, African American female and other
female race patients, respectively. Furthermore, there are 40% of the stomach cancer
patients have the tumor size less than 31mm, 36mm and 34mm for white female, African
American female and other female race patients, respectively.

2.6 Parametric Analysis of Malignant Tumor Sizes for Male
2.6.1 Parametric Analysis of Malignant Tumor Sizes for White Male
The Weibull probability distribution is one of the most commonly used probability
distributions in health science studies. The Weibull probability distribution has the best
32

fit of the malignant tumor sizes data for white male patients. The 3-parameter Weibull
probability distribution and cumulative probability distribution functions are given by

𝛼 𝑥−𝛾 𝛼−1

𝑓(𝑥) = 𝛽 (

𝛽

)

𝑥−𝛾 𝛼

𝑒𝑥𝑝 (− (

𝛽

(2.11)

) ),0 < 𝑥

And

𝐹(𝑥) = 1 − 𝑒𝑥𝑝 (− (

𝑥−𝛾 𝛼
𝛽

(2.12)

) ),0 < 𝑥

where 𝛼, 𝛽, 𝛾 are the shape, scale and location parameters. When 𝛾 = 0, results in the
commonly used two-parameter Weibull probability distribution.

Based on the Chi-square, Komogorov Smirnov and Anderson Darling tests, we identified
the Weibull probability distribution be the best fitted probability distribution for white
male patients. The approximate maximum likelihood estimates of the parameters that
drive the Weibull probability distribution function are 𝛼̂=1.7966, 𝛽̂ =51.362, 𝛾̂=-1.1904.
Thus, the probability density function (pdf) and the corresponding cumulative probability
distribution function (CDF) for the three-parameter Weibull probability distribution are
respectively given by:

1.7966 𝑥+1.1904 1.7966−1

𝑓(𝑥) = 51.362 (

51.362

)

𝑒𝑥𝑝 (− (

𝑥+1.1904 1.7966
51.362

)

)

(2.13)

And
𝐹(𝑥) = 1 − 𝑒𝑥𝑝 (− (

𝑥+1.1904 1.7966
51.362

)

33

).

(2.14)

The expected mean and variance of the malignant tumor size for white male patients are
as follows:

1

(2.15)

𝐸(𝑥) = 𝛾 ̂ + 𝛽 ̂𝛤 (𝛼 ̂ + 1)
= 44.48𝑚𝑚
and
𝑉(𝑥) = 𝛽 2̂ (𝛤

2

(𝛼 ̂ + 1)

−𝛤

2

1
(𝛼 ̂ + 1) )

(2.16)

= 26.30
The graphs of 𝑓(𝑥) and 𝐹(𝑥) are given by Figures 2.11 and 2.12, respectively.
Figure 2.11 below shows that the probability of a white male patient has 20mm and
40mm tumor sizes are 0.0137 and 0.01514, respectively. And the probability of a white
male patients has the tumor size between 20mm and 40mm is 0.304 that is

𝑝(20𝑚𝑚 < 𝑥 < 40𝑚𝑚) = 0.304.
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Figure 2.11: Fitted Weibull Probability Distribution Function of Malignant Tumor Size for White Male

Figure 2.12: Fitted Cumulative Weibull Distribution Function (CDF) of Malignant Tumor Size for White
Male
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Thus, we calculated the expected mean of the malignant tumor size is 44.48 millimeters
and the standard deviation for white male patients is 26.30 millimeters. We also obtained
the confidence interval based on E.q (2.6), that is, we are at least 95% confident that
white male patients’ the true malignant tumor size is in the range from 3.17 millimeters to
104.66 millimeters, that is

𝑝(3.17𝑚𝑚 < 𝑡𝑟𝑢𝑒 𝑡𝑢𝑚𝑜𝑟 𝑠𝑖𝑧𝑒 < 104.66) ≥ 0.95

From Figure 2.12 above. It illustrates that around 80% of the white male patients have the
malignant tumor size less than or equal to 66 millimeters. That is

𝑝(𝑋 ≤ 66𝑚𝑚) ≈ 0.80.

2.6.2 Parametric Analysis of Malignant Tumor Sizes for African American Male

The results of the goodness-of-fit tests that is Chi-square test, Kolmogorov Smirnov and
Anderson Darling test allow us to identify the best-fitted probability distribution function
for African American male patients with stomach malignant tumor is the three-parameter
Weibull probability distribution. We obtained the approximate maximum likelihood
estimates of the three parameters are 𝛼̂=1.9248, 𝛽̂ =57.193, 𝛾̂=-1.2722. Thus, the fitted
probability density function (pdf) and the corresponding cumulative distribution function
(CDF) for African American Male patients are respectively given by:
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1.9248 𝑥+1.2722 1.9248−1

𝑓(𝑥) = 57.193 (

57.193

)

𝑒𝑥𝑝 (− (

𝑥+1.2722 1.9248
57.193

)

),0 < 𝑥

(2.17)

and
𝑥+1.2722 1.9248

𝐹(𝑥) = 1 − 𝑒𝑥𝑝 (− (

57.193

)

),0 < 𝑥

(2.18)

The graphs of the identified three-parameter Weibull probability distribution function
(2.17) and cumulative probability distribution function (2.18) are given by Figures 2.13
and 2.14, respectively.

Figure 2.13: Fitted Weibull Probability Distribution Function of Malignant Tumor Size for African
American Male
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Figure 2.14: Fitted Cumulative Weibull Distribution Function (CDF) of Malignant Tumor Size for African
American Male

From Figure 2.14 above, we can obtain that around 80% of African American male
patients have malignant tumor sizes less than or equal to 72 millimeters. Also,
𝑝(20𝑚𝑚 < 𝑥 < 60𝑚𝑚) = 0.542.

We also calculated the estimated expected mean of the malignant tumor size is 49.46
millimeters and the standard deviation for African American male patients is 27.45
millimeters. Furthermore, we are at least 95% confident that the true mean of the African
American male patients’ malignant tumor size is in the range from 7.2 millimeters to
111.41 millimeters. That is,

𝑝(7.2𝑚𝑚 < 𝑡𝑟𝑢𝑒 𝑡𝑢𝑚𝑜𝑟 𝑠𝑖𝑧𝑒 < 111.41𝑚𝑚) ≥ 0.95.
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2.6.3 Parametric Analysis of Malignant Tumor Sizes for Other Male
Similarly, the results of goodness-of-fit tests, that is, Kolmogorov-Smirnov test
(Stephens, 1974), Anderson-Darling test (T.W. Anderson, 1952) and Chi-Square test (H.
Chenoff, 1954), we have identified that the best-fitted probability distribution function
that characterizes the malignant tumor sizes for the other male race patients is the three
parameter Dagum probability distribution.

Dagum probability distribution is a continuous probability distribution. It is named after
Camilo Dagum, who proposed it in a series of papers in the 1970’s. The Dagum
probability distribution function and cumulative probability distribution function are
shown by equation 2.19 and 2.20, respectively.

f(x; α, 𝑘, β) =

𝑥 αk−1
β
k+1
𝑥 α
β(1+( ) )
β

α𝑘( )

(2.19)

and
−k
x −α

F(x) = (1 + (β)

)

(2.20)

Where k, α, β > 0 and 𝛾 < 𝑥 < ∞. α and k are the shape parameters, β is the scale
parameter and 𝛾 is the location parameter. When 𝛾=0, the four-parameter Dagum
probability distribution reduce to the three-parameter Dagum probability distribution.
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The approximate maximum likelihood estimates of the parameters that derive the
probability distribution function are given by 𝛼̂=5.363, 𝛽̂ =71.69, 𝑘̂=0.25867. Thus, the
Dagum probability distribution function and its cumulative probability distribution are
given below:

f(x) =

5.363∗0.25867−1
𝑥
)
71.69
5.363 0.25867+1
𝑥

5.363∗0.25867(
71.69(1+(

71.69

x

)

−5.363 −0.25867

F(x) = (1 + (71.69)

,0 < 𝑥

(2.23)

)

)

,0 < 𝑥

(2.24)

The expected mean and variance of the malignant tumor size for other male race patients
are as follows:
𝐸(𝑋) = −

𝛽
1
1
𝛤(− )𝛤( +𝑘)
α
𝛼
𝛼

𝛤(𝑘)

, (α > 1)

(2.21)

= 46.88𝑚𝑚
And

𝛽2

𝑉(𝑋) = − α2 (

2α

2
𝛼

2
𝛼

𝛤(− )𝛤( +𝑘)
𝛤(𝑘)

+

(

1
𝛼

1
𝛼

𝛤(− )𝛤( +𝑘)
𝛤(𝑘)

2

) ), (α > 2)

(2.2)

= 789.04

The graphical form of the Dagum probability distribution function 𝑓(𝑥) and its
cumulative distribution function 𝐹(𝑥) are given by Figures 2.15 and 2.16, respectively.
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Figure 2.15: Fitted Dagum Probability Distribution Function of Malignant Tumor Size for Other Male

Figure 2.16: Fitted Cumulative Dagum Distribution Function (CDF) of Malignant Tumor Size for Other
Male
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From Figure 2.16 above. We can see that about 80% of the other male race patients have
the stomach malignant tumor size less than or equal to 68 millimeters. Also, 𝑝(𝑥 ≥
𝐸(𝑥) = 46.88) = 0.459, the probability that the malignant tumor size will be larger than
the expected tumor size.

We also calculated the expected mean of the stomach malignant tumor size is 46.88
millimeters and the variance for other male race patients is 789.04 millimeters. We can
use equation (2.6) to obtain confidence limits as the true size of the malignant tumor.
That is,
𝑝(5.02𝑚𝑚 ≤ 𝑡𝑟𝑢𝑒 𝑠𝑖𝑧𝑒 ≤ 109.56𝑚𝑚) ≥ 0.95.

2.6.4 Comparison of the Malignant Tumor Sizes for Male Patients

In this section, we compared the malignant tumor size for male patients by different race
group. Table 2.2 below displays the best-fitted distributions that characterize the
malignant tumor size for different race groups and the estimated malignant mean tumor
size for male patients in each race group. We found the Weibull probability distributions
are the best fitted distributions that can characterize the behavior of the malignant tumor
size for white and African American male patients, while the Dagum probability
distribution for other male race patients. When we compare the average malignant tumor
size under different races (white, African American and other), we reject the null
hypothesis that they are all the same. The African American male patients have the
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largest expected malignant tumor size, which is 49.46mm, while the white male stomach
cancer patients have the smallest expected malignant tumor size, which is 44.48mm. We
obtained confidence intervals for the true malignant tumor size for all the cases. The
confidence range is 101.49mm, 104.21 and 104.51mm for white male, African American
male and other male, respectively. Such information is useful for the physicians.

Table2.2: statistics of the malignant tumor sizes and confidence intervals for male patients
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Standard
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Deviation

95% Confidence Intervals

44.48

26.30

(3.17,104.66)

49.46
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(7.20, 111.41)

46.88

28.09

(5.02, 109.56)

pdf
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Weibull

American pdf
Other
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We plotted the estimated probability distribution curve of the three-parameter Weibull
probability distribution for white male patients and African American male patients and
the probability distribution curve of Dagum probability distribution for the other male
race patients as shown by Figure 2.17 below. We can conclude that when the malignant
tumor size is below 15 millimeters, the probabilities of white male and other male races
are almost the same and they both are greater than that of African American male. When
the malignant tumor size is between 15 millimeters and 45 millimeters, the probabilities
of African American male and other male race are almost the same, and they have
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probability less than that of white male patients. When the malignant tumor size is greater
than 45 millimeters, white male patients have lower probabilities and the other two
groups cross each other.

Figure 2.17: Fitted Probability Distribution Curves of Malignant Tumor Size for Male Patients

We plotted the cumulative probability distribution curves of malignant tumor size for the
three different race groups for male patients as shown in Figure 2.18 below. When we
fixed malignant tumor size, the white male patients always have higher cumulative
probability than the other two groups. African American male patients have the smallest
cumulative probability of malignant tumor size. The probability of the malignant tumor
size is greater than 84mm are 0.089, 0.123 and 0.088 for white male, African American
male and other male race patients, respectively. Furthermore, there are 40% of the
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stomach cancer patients have the tumor size less than 35mm, 40mm and 37mm for white
male, African American male and other male race patients, respectively.

Figure 2.18: Fitted Cumulative Probability Distribution Curves of Malignant Tumor Size for Male Patients

The previous Table 2.2 demonstrates that the expected mean malignant tumor sizes are
44.48 millimeters for white male patients, 49.46 millimeters for African American male
patients and 46.88 millimeters for the other male race patients. The corresponding 95%
confidence intervals are (3.17, 104.66) for white male, (7.2, 111.41) for African
American male and (5.02, 109.56) for other male race patients.

2.7 Relationship between Malignant/Non-Malignant Tumor and Tumor Size
In order to investigate the relationship between the malignancy of the tumor and the
tumor size, we need to find out the chance that a stomach tumor becomes malignant. To
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better achieve this objective, we conducted a plot to exhibit the probability of a malignant
tumor given a function of the tumor size. The details of the relationship are addressed in
Figure 2.19 below.

Figure 2.19: Probability of Malignant Tumor as a Function of Tumor Size

Figure 2.19 shows an increasing trend between the size of a tumor and the probability of
the tumor to be malignant. When the tumor size is 10 millimeters, it has a 99.6% chance
that the tumor is malignant. Furthermore, we could conclude that it has nearly a 99.99%
chance that the tumor is malignant when the patient has a tumor size of 60 millimeters or
bigger. The plot illustrates that a patient has an extremely high chance to have a
malignant tumor although the size of the tumor is small.
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2.8 Contributions
Table2.3: statistics of the malignant tumor sizes and confidence intervals for stomach cancer patients
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American
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We have developed parametric analysis by defining the probability distributions of
malignant tumor size for different race groups in the United States from 2004 to 2013.
Table 2.3 above summarize the results of the parametric analysis from which we can
obtain the following useful information.
1. We have demonstrated that the mean of cancerous tumor size is different for
gender and race groups.
2. The best fitted probability distribution function for white female patients is
Wakeby probability distribution with mean 42.48 mm and standard deviation
27.64 mm.
3. The best fitted probability distribution function for African American female
patients is Wakeby probability distribution with mean 47.51 mm and standard
deviation 28.66 mm.
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4. The best fitted probability distribution function for other female race patients is
Wakeby probability distribution with mean 45.56 mm and standard deviation
27.96 mm.
5. The best fitted probability distribution function for white male patients is Weibull
probability distribution with mean 44.48 mm and standard deviation 26.30 mm.
6. The best fitted probability distribution function for African American male
patients is the three parameter Weibull probability distribution with mean 49.46
mm and standard deviation 27.45 mm.
7. The best fitted probability distribution function for other race male patients is
Dagum probability distribution with mean 46.88 mm and standard deviation 28.09
mm.
8. The fitted probability distribution functions are essential to develop statistical
inference on the malignant tumor size.
9. The graphical figures of the probability density functions and the cumulative
distribution curves could provide assistances for physicians understand the
probabilistic behavior of the tumor size.
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Chapter 3
Statistical Quantile Regression Model for Malignant Stomach Tumor

3.1 Introduction
The average malignant stomach tumor size is often insufficient to explain the
probabilistic behavior of malignant stomach tumor size. Standard least square estimates
only shows an average effect of the covariates on the average malignant stomach tumor
sizes. Thus, it is desirable to investigate the best-fitted statistical model that will describe
the effects of malignant stomach tumor sizes by using the covariates of race, gender, age
and their interaction terms. As demonstrated in the parametric analysis (Chapter 2) of
malignant stomach tumor size study, we found the more appropriate probability
distributions to describe the probabilistic behavior of the malignant stomach tumor sizes
are highly skewed and follow the Wakeby probability distribution for White female,
African American female and other female race patients; the three-parameter Weibull
probability distribution fits best for White male and African American male patients; and
the Dagum probability distribution for all other male race patients. Besides the fact that
regression curves can provide the summary of the average of the probability distribution,
regression curves with different percentages are able to depict a more complete picture of
the malignant tumor size. This chapter describes the effects of race, gender and age on
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the sizes of malignant stomach tumor by developing a statistical quantile regression
model (R. Koenker, 1978).

The proposed statistical quantile regression model comprehensively describes the effects
of the predictors on the response variable by modeling the relationship between a set of
risk variables (i.e., age, gender, race and their interaction terms) and the specific
percentiles of the response variable (i.e., malignant tumor size). For example, the 50th
percentile of malignant stomach tumor size on patients’ age, gender and race specifies the
changes in the median malignant tumor size as a function of patients’ race, gender, age
and their interaction terms. The effect of the specific predictors (race, gender, age and
their interaction terms) on the median malignant tumor sizes can be compared with its
effect on the other quantiles of malignant tumor size. Statistical median regression is
more robust to outliers than least squares regression, and it is semi parametric because it
avoids assumptions for the parametric distribution of the error process. Statistical quantile
regression models are widely used in many fields such as environmental sciences,
econometrics, survival analysis, among others.

3.2 Data Description

In the formulation of the quantile statistical regression model for the stomach cancer data
was obtained from Surveillance, Epidemiology, and End Results database (SEER).
Figure 3.1 below shows a schematic diagram of the actual data that we used along with
the appropriate covariates. We considered the races of white, African American and
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other; the gender of female and male and the age of the stomach cancer patients as risk
factors, with the quantiles of the malignant stomach tumor sizes as the response variable.
The malignant tumor size is measured in millimeters, and the total number of patients
with malignant tumor size is 11,394. For the patients with the stomach malignant tumor,
there are 7,115 males and 4,279 female patients. Moreover, there are 7,607 white
patients, 1,522 African American patients along with 2,265 other race patients.

Stomach
Cancer
11,394

Race
11,394

White
7,607

African
American
1,522

Gender
11,394

Other
2,265

Male
7,115

Figure 3.1: Schematic diagram of stomach cancer patients

51

Female
4,279

3.3 Stomach Tumor Sizes and Quantile Regression Model
3.3.1 Quantiles and Optimization
The quantile regression model is a conditional quantile given by the predictors. For a
random variable 𝑌 with a cumulative probability distribution function given by

(3.1)

𝐹(𝑦) = 𝑃𝑟𝑜𝑏 (𝑌 ≤ 𝑦).
The 𝜏 𝑡ℎ quantile of 𝑌 is denoted as the inverse function (Koenker 2005), that is,

𝐹 −1 (𝜏) = 𝑄(𝜏) = inf{𝑦: 𝐹(𝑦) ≥ 𝜏},

(3.2)

where 0 < 𝜏 < 1. More specifically, the median regression quantile is given by

(3.3)

𝑄(0.5) = inf{𝑦: 𝐹(𝑦) ≥ 0.5}.

Fox and Rubin (1964) used the piece-wise linear loss function to estimate the quantile
estimators. They also used the ordered sample observations to verify the 𝜏 𝑡ℎ quantile.

For a random sample {𝑦1 , 𝑦2 , … , 𝑦𝑛 } of 𝑌, the sample median can be computed by
minimizing the following equation which is the sum of the absolute deviations, that is,

Sample median=𝑚𝑖𝑛𝜀∈𝑅 ∑𝑛𝑖=1 |𝑦𝑖 − 𝜀|.
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(3.4)

Similarly, the 𝜏 𝑡ℎ sample quantile 𝜀(𝜏) = 𝑄(𝜏) can be computed as a solution of the
optimization problem, that is,

𝑄(𝜏) = 𝑚𝑖𝑛𝜀∈𝑅 ∑𝑛𝑖=1 𝜌𝜏 (𝑦𝑖 − 𝜀),

(3.5)

where 𝜌𝜏 (𝑢) = 𝑢(𝜏 − 𝐼(𝑢 < 0)), 0 < 𝜏 < 1, and 𝐼(. ) is the indicator function.
We proceed to minimize the following sum of squared residuals,

Sample mean= 𝜇̂ = 𝑎𝑟𝑔𝑚𝑖𝑛𝑣∈𝑅 ∑𝑛𝑖=1(𝑦𝑖 − 𝜇)2 .

(3.6)

By solving
𝛽̂ = 𝑎𝑟𝑔𝑚𝑖𝑛𝛽∈𝑅𝑝 ∑𝑛𝑖=1(𝑦𝑖 − 𝑥′𝑖 𝛽)2 ,

(3.7)

we can extend (3.6) to conditional expectation 𝐸(𝑌 = 𝑋 = 𝑥) = 𝑥′𝛽.
Similarly, we can solve the following equation

𝛽̂ = 𝑎𝑟𝑔𝑚𝑖𝑛𝛽∈𝑅𝑝 ∑𝑛𝑖=1 𝜌𝜏 (𝑦𝑖 − 𝑥′𝑖 𝛽),

(3.8)

to estimate the linear conditional quantile function 𝑄(𝜏|𝑋 = 𝑥) = 𝑥 𝑇 𝛽(𝜏),

where 𝛽̂ (𝜏) is denoted an estimate as the 𝜏 𝑡ℎ regression quantile for any quantile 𝜏 ∈
(0,1). There is a special case when 𝜏 = 0.5 which minimizes the sum of absolute
residuals.
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3.3.2 Regression Quantile Estimates

Let 𝑋 = (𝑥1 , 𝑥2 , … , 𝑥𝑛 ) be a random variable and 𝑌 = (𝑦1 , 𝑦2 , … , 𝑦𝑛 ) be the
corresponding 𝑛 observed responses. The statistical quantile regression model is then
defined by

𝑦 = 𝑋 𝑇 𝛽𝜏 + 𝜀𝜏 ,

(3.9)

where 𝛽 = (𝛽1 , 𝛽2 , … , 𝛽𝑝 )𝑇 denotes an unknown vector of parameters and 𝜀 =
(𝜀1 , 𝜀2 , … , 𝜀𝑛 )𝑇 represents a vector of unknown errors terms. The 𝜏 𝑡ℎ regression quantile
can be computed as a solution of

𝑚𝑖𝑛𝛽∈𝑅 [∑𝑦𝑖 ≥𝑥 𝑇 𝛽 𝜏|𝑦𝑖 − 𝑥𝑖𝑇 𝛽| + ∑𝑦𝑖 <𝑥 𝑇 𝛽(1 − 𝜏)|𝑦𝑖 − 𝑥𝑖𝑇 𝛽|],
𝑖

𝑖

(3.10)

and we can obtain the median regression by solving the following function,

𝑚𝑖𝑛𝛽∈𝑅 [∑𝑦𝑖 ≥𝑥 𝑇 𝛽

|𝑦𝑖 −𝑥𝑖𝑇 𝛽|

𝑖

2

+ ∑𝑦𝑖 <𝑥 𝑇 𝛽
𝑖

|𝑦𝑖 −𝑥𝑖𝑇 𝛽|
2

],

(3.11)

which is a special case of (3.10).

In the literature, statisticians are able to estimate the coefficients of the median regression
as a linear programming problem by solving special forms of the simplex algorithm
(Barrodale and Roberts 1973). The simplex algorithm is widely used in many statistical
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scientific areas. Although the computation loops exponentially increase as the sample
size increases, scientists commonly apply the simplex algorithm to the data with sample
size less than 10,000. Alternative approaches have been developed for large data sets.
The interior point approach (Karmarkar 1984) is widely used to solve median regression
problems in which the relevant interior of a constraint set is approximated by an ellipsoid.
The interior point approach has been proven to be better than the simplex algorithm as
well as dealing with large data sets. Excluding the simplex algorithm and interior point
method, there are several heuristic estimations that have been developed to explore the
median quantile regression solutions. The most powerful method is the finite smoothing
algorithm (Madsen and Nelsen 1993). The Newton-Ralphon algorithm utilizes the finite
number of loops to find the parameter coefficients since its smoothing algorithm
approximates the objective regression function with a smoothing function.

To measure the effects of the patients’ age, gender, race and their interaction terms on the
malignant stomach tumor sizes, we have developed statistical quantile regression models
for different quantiles of the distributions of malignant tumor sizes. In this section, we
give a brief introduction for the proposed model and apply the proposed model to the
SEER stomach cancer data set.

The standard least square regression models only compute the average mean effect of
independent variables on the tumor size. Standard least squares assumption of normally
distributed errors does not hold for stomach cancer data base because the malignant
tumor sizes follow Dagum, Weibull and Wakeby probability distributions. Thus, to focus
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only on the average malignant tumor size, we use the standard least square regression
models that probably hide some important elements of the underlying relationship.
Statistical quantile regression has been used most commonly to model the skewed data in
the literature.

In medicine, reference charts provide a collection of the useful quantiles. Comparing with
a simple reference range, quantile curves have merits when the measurement strongly
depends on a covariate such as patient’s age (Cole and Green 1992, Royston and Altman
1994). In survival analysis, a given covariate may have different effects at different
quantile levels. Such effects can be solved by using statistical quantile functions on
survival time (Koenker and Geling, 2001). Statistical quantile regression model can also
be applied in the field of economics (Buchinsky 1998, Machado and Mata 2005). Pokhrel
(2013) discussed the effect of brain tumor sizes by quantile regression model.
Unfortunately, there is no such statistics analysis for stomach cancer until the present
study.

There are several merits that lead us to choose the statistical quantile regression model
rather than the ordinary least squares estimation:
a. The ordinary least squares are inefficient when the errors are highly non-normally
distributed. Since the stomach malignant tumor sizes follow the Dagum, Wakeby
and Weibull probability distributions, the standard least squares assumption of
normally distributed errors fails to hold.
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b. Statistical quantile regression model is invariant to monotonic transformations
and the coefficients 𝛽̂𝜏 are invariant to outliers of dependent variable (Buchinsky,
1994).
c. Quantile regression models can comprehensively describe the conditional
probability distribution of dependent variables (Alex Coad and Rekha Rao, 2008).
d. The probability distribution of malignant stomach tumor sizes is skewed as
revealed in our previous study. Statistical quantile regression model is robust to
the highly skewed probability distributions.

Thus, we proposed the statistical quantile regression methods to model the relationship
between a set of risk factors (i.e., race, gender, age and their interaction terms) and
particular quantiles of the response variable (i.e., malignant stomach tumor size) by
specifying the changes in the quantiles of malignant stomach tumor size. For example, a
median quantile regression of malignant tumor size diagnosed on the malignant stomach
tumor patients specifies the changes in the median tumor size as a function of the
predictors. Similarly, the 25th quantile regression of malignant tumor size diagnosed on
patients specifies the changes in the 25th quantile of tumor size as a function of the
covariates. The effect of patients’ age on the 75th quantile malignant stomach tumor sizes
of white patients can be compared with that of African American patients. Such
information exhibits a more comprehensive picture of the race effect on age and the race
effect on the upper or lower side of the distribution of malignant tumor sizes.
Furthermore, in linear regression models, the regression coefficients represent the mean
change in the response variable for one unit of change in the predictor variable while
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holding the other predictors fixed. By modeling the estimates with a particular quantile of
the response variable for one unit of change in the risk factor, quantile regression allows
us to find the percentiles of malignant stomach tumor size that are affected more by the
specific characteristics of patients.

We proceeded to calculate the coefficient estimates at 19 different quantiles of the
conditional probability distribution through the following statistical quantile regression
model:

𝑄𝜏 = 𝛼 + 𝛽1 𝑅𝑎𝑐𝑒 + 𝛽2 𝑆𝑒𝑥 + 𝛽3 𝐴𝑔𝑒 + 𝛽4 𝐴𝑔𝑒 ∗ 𝑆𝑒𝑥 +
𝛽5 𝐴𝑔𝑒 ∗ 𝑅𝑎𝑐𝑒 + 𝛽6 𝑆𝑒𝑥 ∗ 𝑅𝑎𝑐𝑒 + 𝜀,

(3.12)

where 𝛼 is the model intercept, 𝛽𝑖 ’s are the coefficients and 𝜀 is the error term.
The ordinary least squares estimates require restrictive assumptions of the error terms,
which are identically distributed from normal distribution. By avoiding that, we proceed
to use the statistical quantile regression model on the stomach cancer data which we
obtained from SEER database.
The 𝜏 𝑡ℎ sample quantile can be obtained by solving the following minimization problem

̂𝜏 = 𝑎𝑟𝑔𝑚𝑖𝑛𝑞∈𝑅 [(1 − 𝜏) ∑𝑦 <𝑞(𝑞 − 𝑦𝑖 ) + 𝜏 ∑𝑦 ≥𝑞(𝑦𝑖 − 𝑞)],
𝑄
𝑖
𝑖
Where q is an initial guess for 𝜏th quantile of the sample data (𝑄𝜏 ).
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(3.13)

̂𝜏 , we would also want to introduce a 95% confidence
Based on the point estimate 𝑄
interval for the desired population quantile. In the literature, the interpolated order
statistic approach suggested by Hettmansperger and Sheather (1986) and Nyblom (1992).
The distribution free method has the advantage of robustness against studentization
method because it does not need to assume the normality of the error terms (Kenneth,
Zhou, 1996). The interval should fulfill the following condition:

𝑝(𝑥(𝑑) ≤ 𝑥𝑝 ≤ 𝑥(𝑒) ) ≥ 1 − 𝛼.

Then we need to try out all possible (𝑑, 𝑒) combinations where 𝑑, 𝑒 satisfy the following
conditions:
𝛼

𝑝(𝑥(𝑑) ≤ 𝑥𝑝 ) ≥ 1 − 2 ,
and
𝛼

𝑝(𝑥𝑝 ≤ 𝑥(𝑒) ) ≥ 1 − 2 .
If several combinations achieve our criterion, we need to calculate the length of each
intervals and then take the minimal length.

Figures 3.2-3.5 display the results of our statistical quantile regression for the stomach
cancer data set. In each plot, we utilized 5th to 95th quantiles for the regression
coefficients, which indicate the effect on the malignant stomach tumor size with one unit
change in that variable while other covariates remain the same. The shade regions are
bands of the point wise with at least 95% confidence intervals. For example, Figure 3.2
below represents the estimated conditional quantile function of the malignant stomach
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tumor size of “other” female race. If the other race female patient has 40 millimeters
malignant tumor size then she will be fall in the 50th quantile. On the other side, if we
know the other race female patient falls in the 75th quantile, then we have at least 95%
confident to conclude that she may have the malignant tumor size between 56 millimeters
and 61 millimeters.

Figure 3.2: The estimated intercept parameter by quantile regression for malignant tumor size. The shaded area
depicts at least 95% point-wise confidence band

Figure 3.3 below displays the estimated difference of malignant stomach tumor size
between white patients and other race stomach cancer patients. It shows the negative
effect of malignant stomach tumor size when comparing with other race patients. For
instance, for 60th quantile, we have at least 95% confident that the white patients will
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have the tumor size less than that of other race patients, the difference will between 0 and
13 millimeters.

Figure 3.3: The estimated difference of malignant tumor size between white and other race patients. The shaded area
depicts at least 95% point-wise confidence band

Figure 3.4 below displays the estimated difference of malignant tumor size between
African American patients and other race patients by using our proposed quantile
regression model. It shows the negative effect of malignant stomach tumor size for low
quantiles when comparing with other race patients, as well as a positive effect for upper
quantiles. For instance, for 20th quantile, the African American patients will have the
smaller tumor size than that of other race patients and we have at least 95% confident that
the difference will between 1.5 and 16 millimeters.
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Figure 3.4: The estimated difference of malignant tumor size between African American and other race patients. The
shaded area depicts at least 95% point-wise confidence band

Figure 3.5 below shows the estimated difference of malignant stomach tumor size
between male and female patients, which matches the results obtained from Chapter 2. It
proves that the malignant stomach tumor size for male patients is bigger than that for
females. For example, for 50th quantile, the male patients will have the bigger malignant
stomach tumor size than that of female and we have at least confidence to conclude that
the difference will be 7 and 19 millimeters.
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Figure 3.5: The estimated difference of malignant tumor size between male and female patients. The shaded area
depicts at least 95% point-wise confidence band

The following equations supports the statistical visualization of the first quantile, median
quantile and third quantile regression models with the appropriate estimates of the
coefficients.

The 25th quantile:
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𝑄0.25 = 15.5 − 13.6 ∗ 𝐼(𝑤ℎ𝑖𝑡𝑒) − 8.17 ∗ 𝐼(𝑏𝑙𝑎𝑐𝑘) +
21.9 ∗ 𝐼(𝑚𝑎𝑙𝑒) + 0.125 ∗ 𝑎𝑔𝑒 − 0.27 ∗ 𝑎𝑔𝑒 ∗ 𝐼(𝑚𝑎𝑙𝑒)
+0.14 ∗ 𝑎𝑔𝑒 ∗ 𝐼(𝑤ℎ𝑖𝑡𝑒) + 0.14 ∗ 𝑎𝑔𝑒 ∗ 𝐼(𝑏𝑙𝑎𝑐𝑘).

(3.14)

The median quantile:

𝑄0.50 = 40 − 7.71 ∗ 𝐼(𝑤ℎ𝑖𝑡𝑒) − 3.16 ∗ 𝐼(𝑏𝑙𝑎𝑐𝑘) +
12.72 ∗ 𝐼(𝑚𝑎𝑙𝑒) + 0.003 ∗ 𝑎𝑔𝑒 − 0.136 ∗ 𝑎𝑔𝑒 ∗ 𝐼(𝑚𝑎𝑙𝑒)
+0.092 ∗ 𝑎𝑔𝑒 ∗ 𝐼(𝑤ℎ𝑖𝑡𝑒) + 0.08 ∗ 𝑎𝑔𝑒 ∗ 𝐼(𝑏𝑙𝑎𝑐𝑘)

(3.15)

The 75th quantile:

𝑄0.75 = 60.83 − 0.83 ∗ 𝐼(𝑤ℎ𝑖𝑡𝑒) + 4.16 ∗ 𝐼(𝑏𝑙𝑎𝑐𝑘) −
0.83 ∗ 𝐼(𝑚𝑎𝑙𝑒) + 0.04 ∗ 𝑎𝑔𝑒 − 0.04 ∗ 𝑎𝑔𝑒 ∗ 𝐼(𝑚𝑎𝑙𝑒)
−0.04 ∗ 𝑎𝑔𝑒 ∗ 𝐼(𝑤ℎ𝑖𝑡𝑒) − 0.04 ∗ 𝑎𝑔𝑒 ∗ 𝐼(𝑏𝑙𝑎𝑐𝑘)
+3.83 ∗ 𝐼(𝑚𝑎𝑙𝑒) ∗ 𝐼(𝑤ℎ𝑖𝑡𝑒)
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(3.16)

Table 3.1:Ordinary and Quantile regression estimates: the coefficients on “malignant tumor size” are reported for 19
quantiles.

OLS

Intercept

Race1

Race2

39.288

-3.41

0.5630

Sex 1
13.67

Age

Age*Sex1

Age*Race1

Age*Race2

Sex1*Race1

Sex1*Race2

0.092

-0.186

0.0027

0.0225

1.1503

0.6134

Quantile Regression from 5th to 95th quantiles:
5

1.292

-2.12

-0.153

1.571

0.097

-0.011

-0.010

-0.0022

1.505

2.289

10

2.142

-6.23

1.035

10.49

0.1428

-0.115

0.0476

-0.0045

1.3214

-0.0928

15

7.2490

-10.5

-1.345

14.025

0.1432

-0.168

0.0875

-0.025

2.969

-0.070

20

14.090

-14.7

-8.51

19.78

0.091

-0.2522

0.161

0.1612

0.9002

-0.3607

25

15.50

-13.6

-8.171

21.907

0.125

-0.2731

0.14815

0.148

1.2037

0.76389

30

16.875

-10.9

1.90

21.22

0.156

-0.2702

0.1140

0.0114

2.833

-0.9966

35

27.21

-13.1

-2.788

16.845

0.042

-0.198

0.156

0.1006

-0.9722

-1.496

40

28.5

-5.92

-5.27

16.15

0.0833

-0.1996

0.0422

0.1162

0.7913

0.6221

45

25.178

-0.17

9.494

15.52

0.1785

-0.1883

-0.0357

-0.0101

1.795

-0.6403

50

40.0

-7.71

-3.167

12.727

0

-0.136

0.0952

0.0833

-1.764

-0.1240

55

40.07

-3.99

-7.272

16.59

0.086

-0.219

-0.0095

0.11355

2.186

1.852

60

45.41

-6.30

4.588

7.890

0.0588

-0.1034

0.0446

-0.0588

3.006

1.5233
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49.123

0.876

-0.423

11.26

0.046

-0.1538

-0.0461

0.0538

0.738

0.4307

70

51.4328

3.567

0.3947

13.619

0.104

-0.2051

-0.1044

-0.001

1.4320

1.5859

75

60.833

-0.83

4.1667

-0.833

0.0416

-0.0416

-0.0416

-0.0416

3.833

3.75

80

66.85

-1.85

3.070

9.578

0.05

-0.1785

-0.05

-0.0479

2.7428

4.5012

85

80

-6.6

0

-0.583

0

-0.0833

-0.1667

0

5.2833

5.9166

90

89.85

-0.98

0.1428

-1.714

-0.071

0

0.0714

0.0714

1.714

1.714

95

100

7.12

0

1.374

0

-0.0218

-0.16

0

0.5963

0.0872

Table 3.1 above provides the estimated coefficients of our statistical quantile regression
model from 5th to 95th quantiles. The results include the estimates coefficients for gender,
race, age and their interaction terms. The red numbers denote the significant effect of
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tumor size on that covariate at significant level 0.05. Table 3.1 shows that the variable
age appears to be a statistically significant factor that affects the change in malignant
tumor size for lower quantile regression models. When the other covariates remain at the
same level, for each year increase in age, the statistically significant effects on the
stomach tumor sizes are 0.097, 0.142, 0.143, 0.09, 0.125, 0.156, 0.083 and 0.178,
respectively for the quantile regressions of 5th, 10th, 15th, 20th, 25th, 30th, 40th, 45th. For the
higher quantiles, the patient’s age effect of the conditional probability on the tumor size
is not very significant. The standard ordinary least squares estimation shows that the
stomach tumor size increases 0.092 when the age increases by one unit.

We also found that the interaction term between age and gender always indicates the
significant effects in stomach malignant tumor size from 5th to 80th quantiles. We also
identified that the covariate gender provides significant effect on the tumor size except
the upper quantiles. Since covariate female is the controlling variable, estimated quantile
regression coefficients of gender represent the difference of the malignant tumor size
between male and female patients while the other factors age and race are fixed.

3.4 Discussion

Malignant Tumor size is strongly related to prognosis in the medical research area. In
general, the smaller the tumor, the higher the chances are for long-term survival. The goal
of this study is to find out the importance of the covariate age, gender and race on the
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effect of the malignant stomach tumor size. It is desirable to utilize the relationship
between patients’ demographic information and malignant stomach tumor size in order to
help researchers postulate histology specific etiologic risk factors. We have applied both
the statistical ordinary least squares and statistical quantile regression models to
investigate the effects of the risk factors age, gender, race and their interaction terms on
the malignant stomach tumor size.

The stomach tumor registry data was provided by SEER program. We demonstrated that
patients’ histology classification could lead the differences in the tumor size. We
explored the statistical model of malignant stomach tumor sizes using statistical quantile
regression models that assist to identify the effects of patients’ demographic information
associated with changing tumor size. For example, the probability distribution of stomach
tumor sizes for male patients is always higher than that of female patients.
The estimates of coefficients for the probability distribution of malignant tumor size of
African American patients are lower than those of other race patients for low quantiles,
whereas the middle and higher quantiles are significantly higher. When the covariates
gender and race remain fixed, the predictor age will show a positive effect on the
malignant stomach tumor size for low quantiles.

3.5 Contributions
In this study, we have developed a statistical quantile regression model that include the
effect of gender, age, race and their interaction terms. Having developed this statistical
quantile regression model, we obtained the following useful information:
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1. We demonstrated the effect of patients’ gender, age, race on the malignant stomach
tumor sizes, that will be helpful to the physicians to make their decisions.
2. Based on the results of our statistical quantile regression model, we found that the
malignant stomach tumor size is different between male and female patients. For
instance, for 50th quantile, the malignant tumor size of male patients is 12.7 mm
larger than that of female patients when other covariates hold constant. Such
information allows the medical physicians to treat female and male patients
differently.
3. Our study reveals a significant difference of malignant tumor size for patients among
different groups of races. For example, for 35th quantile, white patients’ malignant
tumor size is 13.1 mm smaller than other race patients’ malignant tumor size.
However, for 45th quantile of African American patients’ malignant tumor size is
9.49 mm bigger than other race patients’ malignant tumor size.
4. Moreover, our work shows that the patients’ age is a significantly contributing factor
for estimating the malignant stomach tumor size. For 25th quantile, the malignant
tumor size increases 0.125 mm for one-year increase in patients’ age.
5. We also have found that a significant interaction exists between age and gender.
6. The developed statistical quantile regression model provides a more flexible and
comprehensive comparison of malignant stomach tumor size. Such information is
essential for medical scientists to improve the treatments for their patients.
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Chapter 4
Statistical Modeling of Malignant Stomach Tumor Size as Function of Age
4.1 Introduction
According to the American Cancer Society, stomach cancer is the fifth leading cause of
cancer and the third leading cause of death from cancer. The exact causes of stomach
cancer are still unknown. There is a total of 11,462 records of stomach patients that were
diagnosed with non-malignant and malignant tumors in United States from 2004 to 2013.
The data was obtained from the Surveillance, Epidemiology and End Results program
(SEER).

Our previous study has shown that malignant stomach tumor sizes significantly differ on
genders and races. The statistical quantile regression model shows that the patients’ age is
an additional significant variable on the size of malignant tumors.

In the present study, we aim to investigate the effect of age on stomach cancer tumor size
for different types of genders and races.
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4.2 White Male Malignant Stomach Tumor Size and Age

From the SEER database, there are 4,945 white male patients with malignant stomach
tumors and about 83% of the cases were aged from 40 to 80 years. Our statistical models
will focus on the majority part of the patients age. Figure 4.1 below shows a scatter plot
of white male stomach patients with malignant tumor sizes in millimeters.

Figure 4.1: Raw data of White Male patients with stomach tumor size in millimeters

The raw data plot doesn’t display any pattern. Therefore, we averaged the patients’
malignant tumor size at each age level. Figure 4.2 below shows the scatter diagram of
averaging malignant stomach cancer tumor sizes as a function of age for white male
patients.
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Figure 4.2: Mean of Malignant Stomach Tumor size for White Male in millimeters

Figure 4.2 above indicates that the curve has an inflexion point almost every three or four
years of age, which makes it difficult to determine a function that characterize the mean
behavior of malignant tumor sizes as a function of age (Kottabi, 2012). In order to
address this issue, we averaged the malignant tumor size within each four-year interval.
That is, we have 10 intervals of 4 years in length.

We denote stomach cancer patients’ age with 𝑎. The corresponding malignant tumor size
as a function of age is denoted by 𝑇(𝑎) in millimeters. The rate of the tumor size 𝑇′(𝑎) is
the derivative of the function 𝑇(𝑎).

The best statistical model that characterizes white male cancer patients with stomach
tumor size is given by the following equation:
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𝑇(𝑎) = 1.49 ∗ 106 + 2.35 ∗ 103 𝑎 − 13.56 ∗ 𝑎2 + 3.84 ∗ 10−2 𝑎3
1

−1.209 ∗ 106 𝑒 𝑎 − 8.908 ∗ 104 log(𝑎) , 40 ≤ 𝑎 ≤ 80.

(4.1)

The evaluation of the quality of the proposed model with respect to 𝑅 2 , 𝑅 2 adjusted and
residual analysis are given in Table 4.1 below:

Table 4.1: White Male Residual Analysis of Stomach Cancer Tumor Size

Sum of Residuals

-0.01018

Sum of Squared Residuals

0.69756

R-square

0.87

Adjusted- R square

0.84

Thus, the proposed statistical model shows a very good quality to predict the malignant
tumor size as a function of age. Given below is a graph of the model along with an
approximate 95% confidence limits. Thus, from Figure 4.3 we can obtain the following
information such that if a white male patient, 60 years old, the approximate expected
malignant tumor size will be about 44.26 millimeters and we are 95% confident that his
tumor size will be between 43.18 and 45.34 millimeters. And on the other hand, if a white
male patient has a 45 millimeters malignant tumor size then his age is almost 52 years
old.
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Figure 4.3: Estimated predicted model with a 95% confidence interval for white male in millimeters

The derivative of Equation 4.1 estimates a measure of the change of the mean malignant
tumor size as a function of age. That is,

𝑇 ′ (𝑎) = 2.35 ∗ 103 − 27.12𝑎 + 11.52 ∗ 10−2 𝑎2
1

+1.209 ∗

106 𝑒 𝑎
𝑎2

− 8.908 ∗

104
𝑎

, 40 ≤ 𝑎 ≤ 80

(4.2)

Thus, if one wants to find the rate of the malignant tumor size at a particular age, they can
use the above function to predict the changing rate of the malignant tumor size. For
instance, if a 61 years old patient, we can conclude that his changing rate of the malignant
tumor size will be 𝑇 ′ (61) = 0.1047 millimeters.
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The classical rate of change (CRC) of mean malignant tumor sizes with respect to age is
given by the following function (Bonsu, 2013, Kottabi, 2012, Chan, 2013)

𝐶𝑅𝐶 =

𝑇(𝑎) 𝑖𝑛 𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑎𝑔𝑒−𝑇(𝑎) 𝑖𝑛 𝑝𝑟𝑒𝑣𝑖𝑜𝑢𝑠 𝑎𝑔𝑒
𝑇(𝑎) 𝑖𝑛 𝑝𝑟𝑒𝑣𝑖𝑜𝑢𝑠 𝑎𝑔𝑒

(4.3)

We repeated some age of the white male stomach cancer patients and we calculated the
tumor size, Equation 4.1, the rate of changing, Equation 4.2, and the classical rate of
change, CRC, Equation 4.3, the results are given in Table 4.2 below:

Table 4.2: Residual Analysis of Rate Change of Mean tumor size for White male

Age

Tumor

Rate of Change(CRC)

Rate=𝑇′(𝑎)

Rate of Residual

48

46.97

-0.0285

-0.7066

0.6781

49

46.50

-0.01

-0.6978

0.6878

50

44.98

-0.0326

-0.655

0.6224

51

45.60

0.0136

-0.5871

0.6007

….

…………. ……………………… ……………….. ………………………….

60

44.26

-0.0047

0.0934

-0.0981

61

44.19

-0.0017

0.1047

-0.1064

Mean of Residual Rate

-0.032

Standard Deviation of Residual

0.6544

Table 4.2 reveals that the residual is quite small as well as the standard deviation, which
indicates that the proposed model is of good quality to characterize the behavior of the
tumor size as a function of age.
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Figure 4.4 below shows how the rate of the mean of the malignant tumor sizes changes as
a function of the patients’ age increases as one would expect. For instance, if a patient 60
years old we can conclude that his changing rate of the malignant tumor size will be
𝑇 ′ (61) = 0.0934 millimeters.

Figure 4.4: Changing Rate of stomach tumor size for white male

4.3 African American Male Malignant Stomach Tumor Size and Age

In this section, we will propose a statistical model of the African American Male stomach
tumor size as a function of age. Figure 4.5 below shows that the curve has a turning point
almost every three or four years of age, thus we focus on the behavior of the average size
of the malignant tumors within a three-year interval.
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Figure 4.5: Mean of Malignant Stomach Tumor size for African American Male

After searching many kinds of nonlinear statistical model, we could not find an
appropriate statistical model to describe the behavior of the malignant tumor size as a
function of age for all the patients. Then we clustered the patients into two groups, 40 to
55 years old and older than 55 years old.

The statistical function that characterizes the stomach cancer tumor size as a function of
age for African American male patients is expressed in the following Equation 4.4 for
patients from 40 years old to 55 years old.

𝑇(𝑎) = 3.849 ∗ 104 + 776.4𝑎 − 4.422𝑎2 − 1.692 ∗ 104 log(𝑎)
+5.439 ∗ 10−23 𝑒 𝑎 , 40 ≤ 𝑎 ≤ 55
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(4.4)

This model that characterizes the malignant tumor size as a function of age for African
American male patients from age 40 to 55 is a good model. It has an 𝑅 2 of 0.86 with 𝑅 2
adjusted of 0.82 and a very insignificant residual mean. A summary of this information is
given in Table 4.3 below:

Table 4.3: African American Male Residual Analysis of Stomach Cancer Tumor Size from 40 to 55 years old

Sum of Residuals

0.00002

Sum of Squared Residuals

0.8252

R-square

0.86

Adjusted- R square

0.82

Figure 4.6 below shows the predicted curve of the mean malignant tumor size as a
function of age along with at least 95% confidence interval for African American male
patients from 40 to 55 years old. Thus, we can obtain the following information such that
if an African American male patient, 50 years old, the approximate expected malignant
tumor size will be about 55.81 millimeters and we are 95% confident that his tumor size
will be between 51.62 and 60 millimeters. And on the other hand, if an African American
male patient has a 50 millimeters malignant tumor size then his age is almost 43 years
old.
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Figure 4.6: Estimated predicted model with a 95% confidence interval for African American male from 40 to 55

The derivative of Equation 4.4 estimates a measure of the change of the mean malignant
tumor size as a function of age for African American male patients between 40 and 55
years old. That is,

𝑇 ′ (𝑎) = 776.4 − 8.844𝑎 −

16920
𝑎

+ 5.439 ∗ 10−23 𝑒 𝑎 , 40 ≤ 𝑎 ≤ 55.

(4.5)

Thus, if one wants to estimate the changing rate of the malignant tumor size at a
particular age, they can use the above function to predict the changing rate of the
malignant tumor size. For example, if an African American male stomach cancer patient,
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48 years old, we can conclude that his changing rate of the malignant tumor size will be
𝑇 ′ (48) = 0.746 millimeters.

Next, we will use the similar process to obtain the statistical model respect to the
malignant tumor size as a function of age for African American male older than 55 years
old. That is,

𝑇(𝑎) = 1.324 ∗ 107 + 3.75 ∗ 105 𝑎 − 4.214 ∗ 103 𝑎2 + 27.94𝑎3
−6.26 ∗ 106 log(𝑎) + 2.791 ∗ 10−33 𝑒 𝑎 , 55 < 𝑎 ≤ 80

(4.6)

This model that characterizes the malignant tumor size as a function of age for African
American male patients older than 55 is a good model. It has an 𝑅 2 of 0.86 with 𝑅 2
adjusted of 0.83 and a very insignificant residual mean. A summary of this information is
given in Table 4.4 below:

Table 4.4: African American Male Residual Analysis of Stomach Cancer Tumor Size older than 55 years

Sum of Residuals

0.00

Sum of Squared Residuals

1.153

R-square

0.86

Adjusted- R square

0.83

Thus, the proposed statistical model shows a very good quality to predict the malignant
tumor size as a function of age for African American male patients older than 55 years.
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Figure 4.7 below shows the predicted curve of the mean malignant tumor size as a
function of age along with at least 95% confidence interval for African American male
patients older than 55 years old.

Figure 4.7: Estimated predicted model with a 95% confidence interval for African American male older than 55

Thus, we can obtain the following information such that if an African American male
patient, 60 years old, the approximate expected malignant tumor size will be about 46.84
millimeters and we are 95% confident that his tumor size will be between 41.56 and
52.12 millimeters. And on the other hand, if an African American male patient has a
48.72 millimeters malignant tumor size then his age is almost 62 years old.
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Then the derivative of Equation 4.6 indicates a measure of the change of the mean
malignant tumor size as a function of age for African American male older than 55 years
old. That is,

𝑇′(𝑎) = 3.75 ∗ 105 − 8.4 ∗ 103 𝑎 + 83.82𝑎2
−6.26 ∗

106
a

+ 2.791 ∗ 10−33 𝑒 𝑎 , 55 < 𝑎 ≤ 80

(4.7)

Thus, we can use the above function to predict the changing rate of the malignant tumor
size for African American male patients older than 55 years old. For instance, if the
stomach cancer patient 60 years old, we can conclude that his changing rate of the
malignant tumor size will be 𝑇 ′ (60) = 0.2636 millimeters.

In order to evaluate the accuracy of the proposed model, we calculated the classical rate
of change of mean tumor size with respect to age by using Equation 4.3, then compared
with the result from Equations 4.5 and 4.7. The results of the residual analysis are shown
in Table 4.5 below:
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Table 4.5: Residual Analysis of Rate Change of Mean tumor size for African American male

Age

Tumor

Rate of

Rate=𝑇′(𝑎)

Rate of Residual

Change(CRC)
53

43.03

0.0086

-0.0979

0.1065

54

46.439

-0.0077

-0.074

0.0663

55

45.36

0.0016

-0.035

0.0366

56

50.30

-0.0177

0.0165

-0.0342

57

54.26

-0.0067

0.0769

0.0836

58

51.89

-0.0034

0.1419

0.1453

59

51.32

-0.0063

0.2061

-0.2124

60

46.84

0.0168

0.2636

-0.2468

61

48.22

0.0079

0.3075

0.2996

62

48.72

0.0022

0.3301

-0.3279

63

44.26

0.0057

0.3429

-0.3372

64

44.19

-0.0366

0.3864

-0.423

Mean of Residual Rate

-0.0703

Standard Deviation of Residual

0.2302

Table 4.5 reveals that the residual is small as well as the standard deviation, which
indicates that the proposed model is of good quality to characterize the behavior of the
tumor size as a function of age.
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Figure 4.8 below depicts the trend of the changing rate of the malignant stomach tumor as
a function of African American male patients’ age increases as one would expect.

Figure 4.8: Changing Rate of stomach tumor size for African American male

4.4 Other Male Malignant Stomach Tumor Size and Age

In this section, we will propose a statistical model of all other male races stomach cancer
tumor size as a function of age. Figure 4.9 below suggests that experiencing a change in
the mean malignant tumor size every three or four years. Thus, we focus on taking the
average size of the tumors within each three-year interval.
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Figure 4.9: Mean of Malignant Stomach Tumor size for other Male

Then the nonlinear regression function that characterized the stomach cancer tumor size
as the function of age for other male race patients is given by Equation 4.8:

𝑇(𝑎) = 2829 + 34.83𝑎 − 0.1405𝑎2 − 1066 ∗ log(𝑎) , 40 ≤ 𝑎 ≤ 80.

(4.8)

The evaluation of the quality of the proposed model with respect to 𝑅 2 , 𝑅 2 adjusted and
residual analysis are given in Table 4.6, below:
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Table 4.6: Other Race Male Residual Analysis of Stomach Cancer Tumor Size

Sum of Residuals

-2.7755e-17

Sum of Squared Residuals

0.7797

R-square

0.88

Adjusted- R square

0.86

Thus, the proposed model has a 𝑅 2 of 0.88, 𝑅 2 adjusted of 0.86, and the very small sum
of residuals, which shows a very good quality to predict the malignant tumor size as a
function of age.

Figure 4.10: Estimated predicted model with 95% confidence interval for other male
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Figure 4.10 above displays the predicted curve of mean malignant tumor size as a
function of age with an approximate 95% confidence limits for other race male patients
with stomach tumor. Thus, we can obtain the useful information such that a 55 years old
other male race patient, the approximate expected malignant tumor size will be about
44.92 millimeters and we are 95% confident that his tumor size will be 42.1 and 47.74
millimeters. And on the other hand, if a patient has a 48 millimeters malignant tumor size
then his age is almost 58 years old.

The following Equation 4.9 is the derivative function of other race male malignant tumor
size as a function of age. That is,

𝑇′(𝑎) = 34.83 − 0.2810𝑎 −

1066
𝑎

, 40 ≤ 𝑎 ≤ 80.

(4.9)

Thus, if the physician wants to find the changing rate of the malignant tumor size at a
particular age of his patients, he can use the above function to predict the changing rate of
his patients’ malignant tumor size.

We calculated the tumor size, Equation 4.8, the rate of changing, Equation 4.9, and the
classical rate of change, CRC, Equation 4.3, the results are given in Table 4.7 below:
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Table 4.7: Residual Analysis of Rate Change of Mean tumor size for Other male

Age

Tumor

Rate of Change

Rate=𝑇′(𝑎)

Rate of Residual

(CRC)
50

48.2718

-0.0284

-0.54

0.5115

51

45.6306

-0.0547

-0.4029

0.3482

52

44.1222

-0.0330

-0.282

0.2489

53

41.9277

-0.0497

-0.1762

0.1264

54

43.9192

0.0475

-0.0847

0.1322

55

44.9266

0.0229

-0.0068

0.0297

56

46.2984

0.0305

0.0582

-0.0277

57

46.1938

-0.0022

0.1112

-0.1135

58

48.1448

0.0422

0.1526

-0.1104

59

47.2388

-0.0188

0.1832

-0.2020

60

45.8488

-0.0294

0.2033

-0.2327

61

45.1314

-0.0156

0.2135

-0.2292

Mean of Residual Rate

0.07378

Standard Deviation of Residual

0.2310

Table 4.7 above reveals that the residual is small as well as the standard deviation, and
such results indicate a good quality of the proposed model to characterize the behavior of
the malignant tumor size as a function of age.
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Figure 4.11: Changing Rate of stomach tumor size for other male

Figure 4.11 above depicts the trend of the changing size of the malignant stomach tumor
for all other male race patients. For instance, if a 57 years old other male race patient, we
can conclude that his changing rate of the malignant tumor size will be 𝑇 ′ (57) = 0.111
millimeters.

4.5 White Female Malignant Stomach Tumor Size and Age

In this section, we will propose a statistical model of the white Female malignant
stomach tumor size as a function of age. Figure 4.12 below assists us to find that the
curve has an inflexion point almost every three or four years of age. Therefore, we focus
on the average size of the malignant tumor within each three-year interval.
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Figure 4.12: Mean of Malignant Stomach Tumor size for white female

The nonlinear regression function that characterizes the behavior of the stomach cancer
tumor size as the function of age is given by the following Equation 4.10. That is,

𝑇(𝑎) = 1.535 ∗ 105 + 111.9𝑎 − 6726 log(𝑎)
1

−1.294 ∗ 105 𝑒 𝑎 − 0.303𝑎2 , 40 ≤ 𝑎 ≤ 80.

(4.10)

The evaluation of the quality of the proposed model with respect to 𝑅 2 , 𝑅 2 adjusted and
residual analysis are given in Table 4.8, below:
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Table 4.8: White Female Residual Analysis of Stomach Cancer Tumor Size

Sum of Residuals

0.0012e-25

Sum of Squared Residuals

0.949

R-square

0.80

Adjusted- R square

0.78

Thus, the 𝑅 2 is 0.80, the 𝑅 2 adjusted is 0.78 and the sum of residuals is small which
indicates the proposed model shows a very good quality to predict the malignant tumor
size as a function of age.

Figure 4.13: Estimated predicted model with a 95% confidence interval for white female

Figure 4.13 above is a graph of the model along with an approximate 95% confidence
limits. Thus, we can obtain the important information such that a white female patient, 64
90

years old, the approximate expected malignant tumor size will be about 40.33 millimeters
and we are 95% sure that her tumor size will be between 39.19 and 41.47 millimeters.
And from the other side, if a white female patient with 41 millimeters malignant tumor
size, then her age is almost 65 years old.

The following Equation 4.11 measures the change of the mean malignant tumor size as a
function of age. That is,

𝑇 ′ (𝑎) = 111.9 −

6726
a

+ 1.294 ∗

105
1

𝑎2 𝑒 𝑎

− 0.606𝑎, 40 ≤ 𝑎 ≤ 80.

(4.11)

In order to evaluate the accuracy of our proposed model, we calculated the tumor size,
Equation 4.10, the rate of change of mean tumor size, Equation 4.11, and the classical
rate of change, CRC, Equation 4.3, and the results of the residual mean are given in Table
4.9 below:

Table 4.9: Residual Analysis of Rate Change of Mean tumor size for White female

Age

Tumor

Rate of Change

Rate=𝑇′(𝑎)
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Rate of Residual

53

40.321

-0.0260

-0.1800

0.15398

54

42.776

0.0608

-0.1742

0.23515

55

40.823

-0.0456

-0.1591

0.11350

56

40.201

-0.0152

-0.1369

0.12170

57

37.194

-0.0747

-0.1094

0.03467

58

38.176

0.0263

-0.0784

0.10483

59

39.548

0.0359

-0.0453

0.08128

60

42.094

0.0643

-0.0114

0.07583

61

41.852

-0.0057

0.0220

-0.02783

62

41.318

-0.0127

0.0543

-0.06708

63

41.286

-0.0007

0.0843

-0.08516

64

40.331

-0.0231

0.1115

-0.13468

65

40.952

0.0154

0.1351

-0.11970

66

40.991

0.0009

0.1545

-0.15364

67

41.211

0.0053

0.1694

-0.16404

68

40.771

-0.0106

0.1792

-0.18993

69

39.833

-0.0229

0.1836

0.20666

Mean of Residual Rate

-0.0134

Standard Deviation of Residual

0.1375
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In Table 4.9 above, the residual is small as well as the standard deviation, which indicates
that the proposed model is of good quality to characterize the behavior of the malignant
tumor size as a function of age.

Figure 4.14 below shows how the rate of the mean of the malignant tumor sizes changes
as a function of the patients’ age increases as one would expect. For instance, if a white
female patient, 61 years old, we can conclude that her changing rate of the malignant
tumor size will be 𝑇 ′ (61) = 0.022 millimeters.

Figure 4.14: Changing Rate of stomach tumor size for white female
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4.6 African American Female Malignant Stomach Tumor Size and Age

In this section, we will propose a statistical model of African American female stomach
tumor size as a function of age. Figure 4.15 below points out that the curve has a change
in the mean malignant tumor size almost every three or four years. Thus, we focus on the
average size of the tumor within each three-years interval.

Figure 4.15: Mean of Malignant Stomach Tumor size for African American female

The best fitted nonlinear regression function that characterized the stomach cancer tumor
size as a function of age for African American female patients with stomach tumor is
expressed in the following Equation 4.12:

𝑇(𝑎) = −2821 − 41.84𝑎 + 1151 ∗ log(𝑎) + 0.1846𝑎2 , 40 ≤ 𝑎 ≤ 80
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(4.12)

This model that characterizes the malignant tumor size as a function of age for African
American female patients is a good model. It has an 𝑅 2 of 0.90 with 𝑅 2 adjusted of 0.87
and a very insignificant residual mean. A summary of this information is given in Table
4.10 below:

Table 4.10: African American Female Residual Analysis of Stomach Cancer Tumor Size

Sum of Residuals

1.587e-17

Sum of Squared Residuals

0.768

R-square

0.90

Adjusted- R square

0.87

Figure 4.16 below displays the predicted statistical regression curve of mean malignant
tumor size as a function of age with an approximate 95% confidence interval for African
American female patients with malignant stomach tumor. Thus, we could obtain the
following information such that if an African American female patient, 43 years old, the
approximate expected malignant tumor size will be about 51.12 millimeters and we are
95% confident to conclude that her tumor size will be between 50.08 and 52.16
millimeters. And on the other side, if an African American female with 54 millimeters,
then her age is almost 79 years old.
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Figure 4.16: Estimated predicted model with 95% confidence interval for African American female

The following Equation 4.13 measures the change of the mean malignant tumor size as a
function of age. That is,

𝑇 ′ (𝑎) = −41.84 +

1151
𝑎

+ 0.3692𝑎, 40 ≤ 𝑎 ≤ 80.

(4.13)

Thus, we can use the above function to predict the changing rate of the malignant tumor
size. For example, if a 68 years old patient, we can conclude that her changing rate of the
malignant tumor size will be 𝑇 ′ (68) = 0.192 millimeters.

Table 4.11: Residual Analysis of Rate Change of Mean tumor size for African American female
Age

Tumor

Rate of Change

Rate=𝑇′(𝑎)
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Rate of Residual

56

51.255

0.0468

-0.611

0.658

57

50.071

-0.023

-0.602

0.579

58

46.199

-0.077

-0.581

0.504

59

51.007

0.104

-0.548

0.652

60

45.454

-0.108

-0.504

0.395

61

46.937

0.032

-0.449

0.482

62

42.874

-0.155

-0.385

0.229

63

45.299

0.1422

-0.310

0.453

64

41.670

-0.080

-0.226

0.146

65

42.381

0.017

-0.134

0.151

66

44.75

-0.179

-0.033

-0.146

67

41.325

0.188

0.075

0.113

68

42.761

0.034

0.192

-0.157

69

49.727

0.162

0.315

-0.153

70

48.577

-0.023

0.446

-0.469

71

53.645

-0.104

0.584

-0.480

72

51.295

-0.043

0.728

-0.772

73

48.925

-0.046

0.878

-0.924

74

43.092

-0.119

1.034

-1.154

75

43.995

0.020

1.196

-1.175

76

44.328

0.007

1.363

-1.356

77

46.121

0.040

1.536

-1.496

78

49.647

0.076

1.714

-1.637

79

54.763

0.103

1.896

-1.793

80

54.552

-0.003

2.083

-2.087

Mean of Residual Rate

-0.077

Standard Deviation of Residual

0.8566

In order to evaluate the accuracy of the proposed model, we calculated the classical rate
of change of mean tumor size, CRC, by using equation 4.3, then compared it with the rate
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of change, Equation 4.13. The results of the residual analysis are displayed in Table 4.11
above. Table 4.11 reveals that the residual is quite small as well as the standard error.
Such results indicate a good quality of the proposed model for the size of malignant
tumor as a function of age.

Figure 4.17: Changing Rate of stomach tumor size for African American female

Figure 4.17 above shows how the rate of the mean of the malignant tumor sizes changes
as a function of the patients’ age increases as one would expect. For instance, a 70 years
old African American female, we can conclude that her changing rate of the malignant
tumor size will be 𝑇 ′ (70) = 0.446 millimeters.
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4.7 Other Female Malignant Stomach Tumor Size and Age

In this section, we will propose a statistical model of all other race female malignant
stomach tumor size as a function of age. Figure 4.18 below shows that the curve has a
turning point for about every three or four years of age, and such result shifts our
attention to average size of the tumor within each three-years interval.

Figure 4.18: Mean of Malignant Stomach Tumor size for other female

The nonlinear regression function that characterized the malignant stomach cancer tumor
size as a function of age for other female patients is given by the following Equation
4.14:

𝑇(𝑎) = 29540 + 139.9𝑎 − 0.3870𝑎2 − 8262 ∗ log(𝑎)
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−1.594 ∗

105
𝑎

(4.14)

, 40 ≤ 𝑎 ≤ 80.

This model that characterizes the malignant tumor size as a function of age for other
female race patients is a good model. It has an 𝑅 2 = 0.84 with 𝑅 2 adjusted of 0.80 and a
very small residual mean. A summary of this information is given in Table 4.12 below.

Table 4.12: Other Race Female Residual Analysis of Stomach Cancer Tumor Size

Sum of Residuals

-4.5598e-17

Sum of Squared Residuals

0.5796

R-square

0.84

Adjusted- R square

0.80

Figure 4.19 below displays the predicted statistical regression curve of the mean
malignant tumor size as a function of age with an approximate 95% confidence interval
for other race female patients. For instance, if a 55 years old stomach cancer patient, the
approximate expected malignant tumor size will be about 46.51 millimeters and we are
95% confident that her malignant tumor size will be between 45.78 and 47.24
millimeters.
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Figure 4.19: Estimated predicted model with 95% confidence interval for other female

The following Equation 4.15 shows the change of the mean malignant tumor size as a
function of age. That is,

𝑇′(𝑎) = 139.904 − 0.7740𝑎 −

8262
𝑎

+ 1.594 ∗

105
𝑎2

, 40 ≤ 𝑎 ≤ 80.

(4.15)

In order to evaluate the accuracy of the results, we calculated the classical rate of change
of mean tumor size with respect to age by using equation 4.3, then compared with the
result from equation 4.15. The results of the residual analysis are displayed in Table 4.13
below.
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Table 4.13: Residual Analysis of Rate Change of Mean tumor size for Other female

Age

Tumor

Rate of Change

Rate=𝑇′(𝑎)

Rate of Residual

(CRC)
51

46.282

-0.0001

-0.2858

0.28577

52

46.427

0.0031

-0.2789

0.28201

53

44.380

-0.0440

-0.2586

0.21461

54

45.388

0.0227

-0.2280

0.25077

55

46.514

0.0248

-0.1899

0.21476

56

46.133

-0.0081

-0.1466

0.13853

57

45.967

-0.003

-0.1001

0.09711

58

45.866

-0.0022

-0.0522

0.05000

59

44.982

-0.0193

-0.0044

-0.01484

60

47.585

0.0578

0.0417

0.01602

61

46.208

-0.0289

0.0853

-0.11422

62

46.216

0.0001

0.1251

-0.12505

63

45.507

-0.0153

0.1603

-0.17569

64

46.098

0.0130

0.1902

-0.17726

65

45.733

-0.0079

0.2141

-0.22201

66

44.995

-0.0170

0.2313

-0.24831

67

45.889

0.0198

0.2415

-0.22178

68

45.867

-0.0004

0.2443

-0.24831

Mean of Residual Rate

0.00011

Standard Deviation of Residual

0.19714
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Table 4.13 reveals that the residual is quite small as well as the standard error. The results
indicate that the proposed model has a good quality to describe the behavior of the mean
malignant tumor size as a function of age. Figure 4.20 below shows the trend of the
changing size of the stomach tumor as a function of patients’ age increases as one would
expect. For instance, if a 64 years old patient, we can conclude that her changing rate of
the malignant tumor size will be 𝑇 ′ (64) = 0.1902 millimeters.

Figure 4.20: Changing Rate of stomach tumor size for other female

4.8 Contributions

In this chapter, we have developed the statistical models for the malignant stomach tumor
size as a function of patient’s age for different types of race and gender, respectively.
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 Statistical models of stomach cancer tumor size for different groups of race and
gender are quite different, and these models consist of linear and nonlinear functions.
We are able to estimate the rate of change in stomach cancer tumor size based on the
proposed statistical models.
 We have shown that the rate of mean stomach cancer tumor size, 𝑇′(𝑎), grows faster
as the patients’ age increases based on all the proposed statistical models.
Both of the residual analysis of the statistical models indicate that we have found
high-quality models of stomach cancer tumor size as the function of patients’ age. Such
outstanding results could assist the stomach physicians to make more accurate decisions.
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Chapter 5
Stomach Cancer Treatment Effectiveness

5.1 Introduction
There are not so many studies that are related to the stomach cancer treatment effects. But
we know that some studies can be found related to whether radiation or surgery shows a
good effect to other cancer patients like breast cancer patients with respect to relapse time
(Cong, 2010). However, the side effects including fatigue, mild skin reactions, upset
stomach, and loose bowel movements from radiation therapy or surgery make it desirable
to avoid surgery or radiation unless it is necessary. Therefore, it is very important for the
physicians to identify the patients who could get benefit from surgery or radiation and
those who could be at the very risk level to receive those treatments. In our study, we
perform the nonparametric, parametric, and decision tree survival analysis to address this
important question. Our parametric and nonparametric analysis identified that the overall
advantage of combined radiation and surgery over radiation only in respect to the
probability of survival times. With the utilization of the decision tree analysis in
conjunction with survival analysis of survival time of stomach cancer patients, we have
concluded that the subgroups of the two treatment groups affect the decision-making
process in choosing the suitable treatment for stomach cancer patients.
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5.2 Stomach Cancer Data
From 2004 to 2013, a total of 2786 patients were diagnosed, of which 2004 are male and
782 are female patients. For male patients, 595 patients received radiation only and 1409
received both radiation and surgery. For female patients, 183 patients received radiation
only and 599 received both treatments.

patients
(2786)

Male
(2004)

Radiation only
(595)

Uncensored
(171)

Censored
(424)

Female
(782)

Radiation and
Surgery
(1409)

Uncensored
(367)

Radiation only
(183)

Censored
(1042)

Uncensored
(83)

Censored
(100)

Radiation and
Surgery
(599)

Uncensored
(203)

Censored
(396)

Figure 5.1: Patient treatments data

This censored data consists of 538 uncensored observations for male patients and 286
uncensored observations for female patients. On the other hand, it has 1466 censored
observations for male and 496 censored observations for female patients as shown in
Figure 5.1. The censored survival times are most likely due to two reasons: 1. The
stomach cancer patients moved out of the study area; 2. The individual survived after the
end of the study period. For male patients, 595 patients had the radiation alone and 1409
took a combination of radiation and surgery. For female patients, 183 took radiation only
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and 599 took both radiation and surgery. Since nearly 70% of the data are censored
observations, we take into consideration two datasets for later analysis.

5.3 Nonparametric Survival Analysis
The Kaplan-Meier estimator is probably the most popular approach. We can use the
empirical survival function: when there is no censoring, the general formula is:

n

# individuals with T > t 1
Ŝ(t) =
= ∑ I(Ti > t).
total sample size
n
i=1

If there is censoring, the method is based on the ideas of conditional probability.so that

Ŝ(t) = ∏ (1 −
rj <t

dj
),
rj

where dj is the number of deaths at time t j and rj is the number of risk at time t j . We can
use the most common method Greenwood’s formula to calculate the variance of the KM
estimator:
var (Ŝ(t)) = (Ŝ(t))2 ∑
rj <t
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dj
.
(rj − dj )rj

Figure 5.2: Survival curves of two treatments for male patients

Figure 5.3: Survival curves of two treatments for female patients
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Kaplan-Meier estimates of the survival curves of survival time for the two treatment
groups for male and female patients are shown in Figure 5.2 and 5.3, respectively. In
Figure 5.2 and 5.3, the two curves show they are significantly different and do not cross
each other. Thus, it shows the patients who have surgery and radiation always have the
better survival rate than that of patients who only receive radiation treatment.

An important advantage of the Kaplan–Meier curve is that it can take into account some
types of censored dataset, which exists if a patient withdraws from a study, is lost to
follow-up, or is alive without event occurrence at last follow-up. On the plot, small
vertical tick-marks indicate individual patients whose survival times have been rightcensored. When no truncation or censoring occurs, the Kaplan–Meier curve is the
complement of the empirical distribution function. The Kaplan-Meier curve is the most
common method to describe survival characteristics. The probability of surviving to any
point is estimated from the cumulative probability of surviving each of the preceding
time intervals. Although the probability calculated at any given interval is not very
accurate because of the small number of events, the overall probability of surviving to
each point is more accurate. However, Kaplan-Meier plot is not commonly used to
compare the true mean effectiveness of the two treatments. In the present study, we
perform actual nonparametric analysis utilizing Wilcoxon (Wilcoxon, 1963) rank sum
test and Peto & Peto (Peto, 1972) modification of the Gehan-Wilcoxon test (Gross and
Clark, 1975). By utilizing the two different nonparametric tests, we found the information
in Table 5.1 below, which shows that the combination of the two treatments (radiation
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and surgery) is more effective than using the single treatment (radiation) which is
consistent with Figure 5.2 and 5.3.

Table 5.1: Test the difference of means of two treatments for male and female patients

Male

Female

Chi-Square

Male

Female

Male

Degree of freedom

Female
P-value

Log-Rank

92

96.5

1

1

7.963e-22

8.805e-23

Peto & Peto
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111

1

1

1.967e-24

6.130e-26

5.4 Parametric Survival Analysis
In a parametric model, we assume the distribution of the survival curve to be known and
the model are specified. Then the hazard function and the effect of any covariates can be
obtained. First, we analyzed the censored dataset and found the generalized gamma
distribution can be best characterized the behavior of survival time for male and female
patients in different treatment groups, and the corresponding maximum likelihood
estimator (MLE) is shown in Table 5.2. A graphical presentation of the cumulative
distribution function (CDF) for male and female patients in radiation treatment group are
shown by Figure 5.4 and 5.5 where the Kaplan-Meier curve and its 95% confidence band,
as well as CDF of the fitted generalized gamma distribution, are plotted.
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Table 5.2: Estimated parameters and log-likelihood of Generalized Gamma Distribution

Male

Female
mu

Male

Female

Male

Sigma

Female
Q

Male

Female

Log-Likelihood

Total

3.977

3.482

2.139

1.932

0.850

0.970

-2981

-1507.9

Radiation

2.893

2.271

2.002

1.545

1.083

0.862

-805.5

-340.8

Radiation

3.851

3.277

1.897

1.562

1.374

1.812

-2108

-1109.5

and Surgery

Figure 5.4: Fitted General Gamma Distribution of Radiation group for male patients
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Figure 5.5: Fitted General Gamma Distribution of Radiation group for female patients

From Figures 5.4 and 5.5 above, the generalized gamma probability distribution seems to
be a good fit for the survival time of male and female stomach cancer patients in the
radiation treatment group. The fitted survival plots of the generalized gamma probability
distribution are very close to the Kaplan-Meier survival plots and they are inside the 95%
confidence limits of Kaplan-Meier survival plots.
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Figure 5.6: Fitted Distribution curve of Radiation and Surgery group for male

Similarly, we perform the same parametric analysis for male and female patients in the
combination of radiation and surgery treatment group, and based on the goodness-of-fit
test results, we have identified the generalized gamma distribution is the best fitted
probability density function for the patients in both radiation and surgery treatment group.
The corresponding maximum likelihood estimators are given in Table 5.2 and the plots of
the cumulative distribution function are shown in Figure 5.6 and 5.7.
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Figure 5.7: Fitted Distribution curve of Radiation and Surgery group for female

From Table 5.2, we know the survival time of the two treatment groups are both from the
generalized gamma probability distribution. Then the log-likelihood ratio test could be
performed to test the hypothesis, that is,
𝐻0 : 𝜇1 = 𝜇2 = 𝜇 𝑣𝑠. 𝐻1 : 𝜇1 ≠ 𝜇2 .
And the log-likelihood ratio test statistics is given below, That is,
𝑇 = −2[𝑙(𝜇,𝜇) − 𝑙(𝜇1 − 𝜇2 )].

After the calculation, we found the test statistics are 𝑇1,𝑑𝑓=1 = 14.07 (male) and
𝑇2,𝑑𝑓=1 = 12.27 (female), and from the Chi-square distribution we found that the p-value
are 0.0001 and 0.0004 for male and female patients respectively. Therefore, we can
conclude that there is a significant difference between the two treatment groups for male
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and female patients, which is consistent with the previous conclusion when using the
nonparametric test.

On the other side, for the uncensored dataset, we have 171 male patients in radiation
treatment only and 367 male patients in radiation and surgery group. For female patients,
we have 83 patients with radiation only and 203 patients are treated with the combination
of radiation and surgery. Through goodness-of-fit tests which included Chi-Square,
Kolmogorov-Smirnov and Anderson-Darling tests, we have identified that the best fitted
parametric distribution function are general Pareto probability distribution for male
patients with radiation only, log-logistic probability distribution for male patients with
both radiation and surgery, Weibull distribution for female patients treated with radiation
only and lognormal probability distribution for female patients in both radiation and
surgery group. We have already identified the consistent results from the parametric and
nonparametric test for censored database. Then we were only considering the censored
data for further analysis.

5.5 Decision Tree Analysis
We are applying the decision tree analysis to partition the subject data as a function of the
malignant tumor size and age of the patient. Decision tree analysis can be used to
homogenize the information by separating the database into several different sub-groups
based on similarity of survival time to treatment. Decision trees are helpful, not only
because they are graphics that help you “visualize” what you are thinking, but also
because making a decision tree requires a systematic, documented thought process. For
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instance, survival decision analysis provide the natural identification of predictive groups
among stomach cancer patients, and the representation tree plots can help physicians to
make early decisions regarding the treatments.

We performed the exponential decision tree analysis (Bacchetti, 1995) to reduce the
impurity within nodes by partitioning based on the risk factors using a specified loss
function. We denote the hazard rate within a given node as ℎ(𝑦) = 𝜆𝑗 for all 𝑦 in group 𝑗,
thus the survival function within each node will be an exponential function. The loss
function for the node 𝑡 is shown by the following function, that is,

𝑅(𝑡) = −𝐿̂(𝑡) = 𝐷𝑡 − 𝐷𝑡 log (

𝐷𝑡
)
𝑌𝑇

Where 𝐷𝑡 = ∑𝑖 𝑑𝑖 is the number of complete observations and 𝑌𝑡 = ∑𝑖 𝑦𝑖 is the total
observed event time.

Our goal is to compare the two different treatments together instead of single treatment
only. We let the maximum tree depth to 3 and the complexity parameter 0.02. The trees
of radiation only and both radiation and surgery treatment for male are shown in Figure
5.8 and Figure 5.9, respectively.
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Figure 5.8: the trees of male patients in radiation group
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Figure 5.9: the trees of male patients in radiation with surgery group

From Figure 5.8 and 5.9, we can see that the radiation treatment group of male patients is
divided into 6 subgroups from left to right, which are denoted by R1, R2, …, R6 for
future analysis and both the radiation and surgery treatment group patients are divided
into 4 subgroups from left to right, which are denoted by RS1, RS2, RS3, RS4. For
instance, R1 group means the male patients who are aged above 76 and whose tumor size
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are bigger than 44 millimeters take the radiation treatment only. And R5 group indicates
that the male patients who are aged below 76 and whose tumor size between 28 and 58
millimeters. Also for the patients took both radiation and surgery, the RS1 group means
the male patients who are aged above 70 and tumor size are bigger than 40 millimeters.
As well in Figure 5.10 and 5.11, for female patients, the radiation treatment group is
divided into 7 subgroups, R1, …, R7, and the radiation and surgery group is split to 6
subgroups, RS1, …, RS6.

Figure 5.10: the trees of female patients in radiation group
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For instance, from Figure 5.10 above, R3 group means the female patients who aged
above 84 and whose tumor size between 34 and 56 millimeters take the radiation only.
And R6 group means the female patients who aged less than 74 and whose tumor size
between 24 and 34 millimeters.

Figure 5.11: the trees of female patients in radiation with surgery group
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From Figure 5.11 above, we could know that the RS1 group means the female patients
who aged above 68 and with the tumor size bigger than 48 millimeters took the radiation
and surgery together. And the RS5 group means the female patients who aged less than
62 with tumor size between 40 and 48 millimeters.

Figure 5.12: Survival curves of male patients in different subgroups

In Figure 5.12 above, we plot the Kaplan-Meier survival curves of different subgroups
together to compare the treatment effect for different subgroup patients. Using the
decision tree analysis, we can clear to see the survival probability for each different
subgroup patients. For example, a male patient whose age is below 76 and tumor size is
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between 58 and 60 millimeters with radiation treatment only would have the lowest
survival probability since the patients in R4 are the lowest line in Figure 5.12.

Therefore, we could group the male stomach cancer patients into three different
subgroups which identify the effectiveness of treatment with radiation versus radiation
and surgery by using the results of the decision tree analysis. For instance, the survival
plot of RS1 is very close to R5, which suggests us that for male patients whose age is
between 70 and 76 with tumor size between 40 and 58 millimeters, the combination of
radiation and surgery shows no advantage over radiation only. Thus, the physicians
should guide the patients not to consider receiving surgery. From Figure 5.12, we
summarize below when the treatment with radiation only and radiation with surgery are
almost equally effective:

(1). RS4, RS3
(2). R2, R3, R5, R6, RS1, RS2
(3). R4, R1
Thus, we found very important results which can recommend stomach doctors to give
information to their patients whether they can receive radiation only instead of receiving
radiation with surgery when they are equally effective to stomach cancer patients in the
same age level with certain size of tumor.

Similarly, we plot the survival curves of each subgroup for female patients in Figure 5.13
by using the decision tree analysis results from Figure 5.10 and 5.11. We also group
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female stomach cancer patients into three clusters for identifying the effectiveness of
treatment with radiation versus radiation and surgery. Below are the three clusters:
(1). RS5, RS6
(2). R6, R7, RS1, RS2, RS3, RS4
(3). R1, R2, R3, R4, R5
During each cluster, they have almost the same treatment effect for female patients, our
results would help the physicians to make the decision for stomach cancer patients who
could only do treatment with radiation when the patients are in the appropriate age and
tumor size intervals.

Figure 5.13: Survival curves of female patients in different subgroups
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5.6 Contributions

In this study, we perform the nonparametric and parametric analysis for comparing the
treatment effect for male and female stomach cancer patients, respectively. Our result
shows that the patients who receive the combination of radiation and surgery have a
significant effect than the patients who receive the radiation treatment alone regarding the
survival time of stomach cancer patients. However, the decision tree analysis gives us the
more powerful result. Based on the decision tree analysis, we found a more detailed
treatment difference between the subgroups. For instance, for male patients whose age is
between 70 and 76 with tumor size between 40 and 58 millimeters, the combination of
radiation and surgery shows no advantage over radiation only, which can help the
physicians to choose the suitable treatment for stomach cancer patients.
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Chapter 6
Future Research

Stomach cancer, the third leading cause of death in the world, not much research has
been done in comparing to Breast cancer, Lung cancer, Colon cancer, among others. The
study in this dissertation opens up several directions for future research. One direction
concerns the involvement of identifying the risk factors. What causes stomach cancer?
We need to identify the risk factors that cause stomach cancer. Unfortunately, we do not
have the necessary data to develop such a model to statistically identify the significant
risk factors, interactions, so that we will be able to predict if a patient is a potential
candidate for stomach cancer. Once such data is available we will pursuit the
development of such an analytic model.

In addition to parametric analysis, we believe that Bayesian analysis is applicable in the
behavior of the malignant tumor size in the stomach. Preliminary studies of the present
data indicate a small significance difference in the approximate maximum likelihood
estimates of the parameters that drive the probability distribution function. With the
applicability of Bayesian analysis, we will improve the estimates of the malignant tumor
size. For instance, we found the three-parameter Weibull probability distribution can be
best describe the behavior of malignant tumor size for white male stomach patients. First,
we could use bootstrapping method to select the random sample. For each sample set, we
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will have appropriate approximate estimates for each of the three parameters. Then, we
can calculate the mean, standard deviation, variance, kurtosis, among others. Next, we
can identify the one with largest variance, to be a random variable. Parametric analysis of
the approximate estimates of the chosen parameter that is treated as random variable
could help us to identify the prior probability distribution. For the loss function, we could
use the most commonly used mean square error loss function, Higgins-Tsokos (Higgins
and Tsokos, 1981) loss function. Then we proceed with Bayesian analysis to obtain
Bayesian estimates of the reject parameter that will better than the parametric estimates.

Another direction concerns the modeling approach to survival analysis. Since our SEER
dataset only contains patients’ age, tumor size, race, gender and treatment, which is very
difficult for us to apply the Cox proportional hazard model due to the strong assumptions
that need to be verified. Thus, we could develop a statistical model, 𝑅𝑡 = 𝑓(𝑥1 , 𝑥2 , … 𝑥𝑛 ),
with the response being the time of death of a stomach cancer patient and the independent
variables are the cause of him/her death. Thus, having such a statistical model, we would
predict the time of death of a given patient as a function of the patients’ information.
Moreover, utilizing surface analysis controls the significant variables and enables us to
maximize the survival time for stomach cancer patients.
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